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Abstract
Primary Amine Oxidase (PrAO) is an enzyme with a variety of physiological roles. It
catalyses the oxidative deamination of primary amines to the corresponding
aldehydes. PrAO converts amines such as methylamine and aminoacetone to reactive
compounds that can damage small blood vessel proteins. It also acts as a vascular
adhesion protein (VAP-1) where it is essential for the migration of leukocytes through
the vascular endothelium. Inhibitors of PrAO have been reported to have anti-cancer,
anti-diabetic and anti-inflammatory action. In this study we explore the interaction
between dietary phytochemicals and Bovine PrAO.

Methylxanthines (MXs) are food alkaloids having a positive association with good
health. Of several MXs we examined, only caffeine and theobromine were found to
be inhibitors of PrAO. Structure activity relationships along with in silico modelling
and inhibition studies allowed us to identify a unique site for MX binding to PrAO.
Green Tea extracts also inhibited PrAO but these reactive compounds were shown to
give complex inhibition patterns due to the formation of non-enzymatic reaction
products and interference in assay procedures. Despite these difficulties we found
some evidence of direct inhibition of PrAO by Green Tea catechins. A number of other
compounds tested showed a similar ability to inhibit PrAO.
Taken together these studies show the potential for a variety of dietary compounds to
inhibit the activity of this key enzyme. The role of PrAO inhibition by such
phytochemicals in health and disease is discussed.
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CHAPTER 1
Introduction

1

1.0

Diet and health benefits

Diet analysis is an area of increasing interest in terms of health benefits and disease
prevention. Diets, such as the Mediterranean diet, that are rich in fruits, vegetables,
legumes and cereals accompanied by high olive oil consumption, have been shown to
be clinically relevant in the amelioration of mortality from diseases, including Type II
diabetes, cancer, cardiovascular disease as well as Parkinson’s and Alzheimer’s
disease (Lourida et al., 2013; Singh et al., 2014).

The residents of the Japanese island of Okinawa are known for their longevity, having
a high number of centenarians and a markedly low incidence of age-related disease
(Suzuki et al., 2016). Their longevity is thought to be mainly due to the avoidance, or
delay, of the onset of major age-related illnesses such as cancer, heart disease, stroke
and diabetes. These health benefits are attributed to a diet rich in vegetable and fruit
intake suggesting an important role for phytonutrients, minerals, vitamins and
antioxidant-containing foods in the maintenance of good health (Willcox et al., 2014).
Particular dietary habits, such as the daily consumption of various teas and coffee have
been extensively studied and are associated with numerous health benefits and the
amelioration of various diseases (da Silva Pinto, 2013; Ferrucci et al., 2014; George
et al., 2008). For instance, a study by O’Keefe et al in the United States, where over
400 million cups of coffee are consumed daily has shown, in both human and animal
trials, that regular coffee consumption is associated with reduced vascular disease,
type II diabetes and obesity (O'Keefe et al., 2013). A recent study of the relationship
between coffee consumption and mortality in diverse European populations showed
that coffee drinking was associated with reduced risk of death from various causes
such as cardiovascular disease and cerebrovascular disease (Gunter et al., 2017).
2

The principal bioactive present in coffee, caffeine, is the subject of particular interest
in disease prevention. A large-scale study by (Furman et al., 2017) showed that
moderate caffeine consumption suppressed systemic inflammation, caused by
inflammasome activation, which could account for its correlation with decreased
mortality. Arendash and Cao (2010) in a study linking the reduction of Alzheimer’s
disease and caffeine consumption found a direct correlation between the reduction of
amyloid plaque formation and caffeine consumption in mice. Moreover, Chen et al.
(2010) have shown that caffeine has a protective effect against the onset of
Alzheimer’s and Parkinson’s disease: although the underlying mechanisms are not
fully understood, it was postulated that caffeine aids in keeping the blood-brain barrier
intact. Thus, caffeine may act to prevent blood-brain barrier leakage a possible
contributor to the progression of both Alzheimer’s and Parkinson’s pathogenesis.
Although there are many positive health benefits associated with moderate intake of
caffeine, excessive consumption (considered as being over 5 cups of coffee or excess
of 400 mg of caffeine a day (see Nehlig, 2015)) can have negative effects. Mood
alteration such as increased anxiety or motor control impairment has been reported
(Smith, 2002) as has sleep deprivation with some users experiencing withdrawal
symptoms (Rogers et al., 2005).

Green tea is a commonly consumed beverage, particularly in Asia, but is growing in
popularity in the West due to increasing reports of health benefits (Mak, 2012).
Notable health benefits associated with green tea consumption include the prevention
of cancer, cardiovascular disease, type II diabetes and obesity. Many of these reported
benefits are ascribed to the high polyphenol content of green tea. Catechins are the
3

principal polyphenol components of Green Tea (Chacko et al., 2010). Catechins are
Flavan-3-ols, derived from flavans, that contain the 2-phenyl-3,4-dihydro-2Hchromen-3-ol skeleton as part of their structure (see Fig. 1.1).

Fig. 1.1. Structures of some Green Tea catechins considered in this study.
http://www.chemspider.com/Chemical-Structure

The mechanistic link between ingestion of specific dietary components and health is
not well understood (Kozlowska and Szostak-Wegierek, 2014). Thus, while a diet
rich in fruits and vegetables can be linked to good health, the specific components of
the diet that confer a health advantage are not known. In recent years, attention has
focused on phytochemicals such as polyphenols, catechins and methylxanthines.
However, our understanding of the molecular mechanisms underlying such effects are
still at an early stage (Franco et al., 2013; Kozlowska and Szostak-Wegierek, 2014;
Sarriá et al., 2015). It has been shown that methylxanthines such as caffeine are able
to bind to adenosine receptors and much of their health benefits are attributed to this
property. Catechins, the main polyphenols in green tea are known to have antioxidant
properties (Rashidinejad et al., 2015) and to regulate gene expression and prevent
DNA methylation and damage (Fujiki et al., 2015). These observations may account
for some of the health benefits associated with these compounds and raise the
4

possibility that there may be other important physiological targets yet to be explored.
(Franco et al., 2013; Fukushima et al., 2009; Kozlowska and Szostak-Wegierek, 2014;
Rashidinejad et al., 2015; Sarriá et al., 2015).

1.1

Amine Oxidases

Amine oxidases (AOs) are ubiquitous enzymes among living species and are
responsible for the breakdown of mono and poly-amines from the diet and the
environment (Gong and Boor, 2006). AOs are involved in a wide range of
physiological functions such as the removal of toxic amines; neurotransmitter
breakdown, leukocyte recruitment and collagen stabilisation (Baker et al., 2007). AOs
catalyse amine catabolism by their oxidation into an aldehyde, ammonia and hydrogen
peroxide products (Fig. 1.2; Agostinelli et al., 2010).

R-CH2NH2 + O2 + H2O  R-CHO + NH3 + H2O2
Fig. 1.2: Amine Oxidase-catalysed deamination reaction. On the left, a primary amine, oxygen and
water are transformed to (on the right) the corresponding aldehyde, ammonia and hydrogen peroxide
as products.

There are five main classes of amine oxidases, namely; diamine oxidases (DAO) E.C.
1.4.3.22, monoamine oxidases (MAO) E.C 1.4.3.4, lysyl oxidase (LOX) E.C 1.4.3.13,
polyamine oxidases (PAO) E.C 1.5.3.13 and primary amine oxidases (PrAO) E.C
1.4.3.21 (BRENDA, 2015). These five AOs can be further divided into two main
groups based upon their cofactor preferences (see Table 1.0).

5

Table 1.0 The five Classes of Amine Oxidases subdivided by Cofactor type (see Yraola et al.,
2009; Black and Whetstine, 2012; Binda et al., 2013; Tomitori et al., 2012; Agostinelli et al.,
2010)

Flavin adenine dinucleotide (FAD)

2,4,5-trihydroxyphenylalanine quinone (TPQ)

used as cofactor

used as cofactor

MAO

PAO

PrAO

DAO

LOX

E.C 1.4.3.4

E.C 1.5.3.13

E.C 1.4.3.21

E.C. 1.4.3.22

E.C 1.4.3.13

Spermine

Benzylamine

Histamine

Amino Groups in

Spermidine

Methylamine

Cadaverine

lysine residues in

Aminoacetone

Putrescine

collagen and

Substrates Noradrenaline
Dopamine
Spermidine
Benzylamine

elastin

Inhibitors

Chlorgyline

MDL. 72,527

Semicarbazide

Semicarbazide

Semicarbazide

Location

Mitochondria

Intracellular

Cell

Intracellular

Extracellular

Leukocyte

Breakdown of

Formation of

Adhesion,

Histamine

Extracellular

Surface/Plasma

Function

Breakdown of

Cell Growth

Neurotransmitters

Breakdown of

Matrix

Primary Amines

MAO and PAO belong to a group that uses flavin adenine dinucleotide (FAD) as
cofactor while LOX, PrAO and DAO belong to a group that uses 2,4,5trihydroxyphenylalanine quinone (TPQ) as cofactor (Yraola et al., 2009). MAOs are
mitochondrial enzymes responsible for the breakdown of neurotransmitters. MAO
exists in two forms designated MAO-A and MAO-B that differ in terms of substrate
specificity and inhibitor sensitivity. MAOs are targeted extensively in the treatment of
mental health diseases such as depression, neurological diseases and Alzheimer’s
disease (Binda et al., 2013). PAOs, on the other hand, are known to break down
secondary amines including, spermidine and spermine which are involved in cell
growth (Tomitori et al., 2012).
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Of the TPQ-containing group: LOX is responsible for the crosslinking of an amino
group of lysine with residues of other peptide strands which acts to stabilise the
extracellular matrices of collagen and elastin (Black and Whetstine, 2012). DAO is
primarily responsible for the breakdown of amines, such as, putrescine, spermidine
and cadaverine (Armenta and Blanco, 2012). PrAO is known to oxidise primary
amines and has received a lot of attention due to its multiplicity of functions (see
O’Sullivan et al., 2004). Studies have shown a correlation between disease and
abnormal or elevated PrAO levels in the body (Wong et al., 2013). Further details of
the structure and function of PrAO are given below.

1.2

PrAO: An Introduction

PrAO (EC 1.4.3.21) is an enzyme that can be found either membrane bound or freefloating in plasma (Wong et al., 2014). PrAO belongs to the oxidoreductase
(deaminating) family of enzymes. The International Union of Biochemistry and
Molecular Biology (IUBMB) classify such enzymes as follows:
“a group of enzymes that oxidize primary monoamines but have little or no activity
towards diamines, such as histamine, or towards secondary and tertiary amines. They
are copper quinoproteins (2,4,5-trihydroxyphenylalanine quinone) and, unlike EC
1.4.3.4, monoamine oxidase, are sensitive to inhibition by carbonyl-group reagents,
such as semicarbazide. In some mammalian tissues the enzyme also functions as a
vascular-adhesion protein (VAP-1)” (BRENDA, 2015) (see section 1.3).
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PrAO has been given different names over the years being variously known as
benzylamine oxidase and chlorgyline resistant oxidase (CRAO; Buffoni and
Blaschko, 1964; Clarke et al., 1982). In recent years PrAO was often commonly
named as Semicarbazide Sensitive Amine Oxidase (SSAO) since it is potently
inhibited by this compound. At present, the recommended nomenclature is to refer to
this enzyme as Primary Amine Oxidase (PrAO) (O'Sullivan et al., 2004).
When it is membrane bound, PrAO is found in high quantities in vascular, kidney,
lung and adipose tissues and is known to increase in activity when associated diseases
are present. For example, high PrAO activity in diabetic patients with vascular disease
was reported at first clinical diagnosis indicating that high PrAO activity precedes the
appearance of vascular complications (Göktürk et al., 2003). The involvement of
PrAO in diseases such as diabetes, vascular diseases, neurological disease,
inflammation and obesity is not well understood (see Section 1.6 for further details).

PrAO has been shown to be involved in the pathogenesis of inflammatory diseases by
mediating the migration of leukocytes into tissue and promoting an inflammatory
response. Since the action of PrAO, either in the oxidative deamination of

endogenous amines or in its role as a vascular adhesion protein (see section 1.3),
requires its catalytic activity to be intact, PrAO inhibition appears to be a logical
strategy to limit inflammation in various diseases.

Some of the deleterious effects attributed to elevated PrAO levels are thought to be
due to the toxic products formed during the oxidation of endogenous substrates such
as aminoacetone (a product from adrenaline and creatinine metabolism) and
methylamine (a product of amino acid catabolism). These endogenous substrates are
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oxidised into highly reactive formaldehyde and methylglyoxal which are cytotoxic
and genotoxic compounds (Hernandez et al., 2006a; Ullah et al., 2013; Wong et al.,
2014).

1.2.1

PrAO Molecular Structure

PrAO is a dimeric enzyme that is 180 kDa in size (Fig. 1.3); each 90kDa monomer
has a TPQ moiety as cofactor in the active site along with a copper atom in close
proximity to the metal (Peet et al., 2011).

Fig. 1.3: Structure of dimeric PrAO (PDB-2PNC). On the left PrAO is shown as a stick model
highlighting TPQ at the active site. The two monomers are shown as “A” green and “B” pink. The
right-hand image depicts PrAO as a space filling model highlighting the funnel (concentric circles)
leading to the active site entrance. It also shows the junction of the two monomers and the location of
the joining hairpin “arms” of the dimer structure. (Sanner, 1999).

9

The structures of some copper containing amine oxidases (CuAOs) have been resolved
by X-ray crystallography and they show a highly conserved active site across all
species i.e. human, bovine, and murine. The active site is deeply buried within the
structure and is accessed by a “funnel” formed by the D3 and D4 domains. TPQ, the
quinone cofactor, is formed post-translationally by a non-enzymatic oxidation reaction
of the amino acid tyrosine (Tyr471 in humans) in the presence of molecular oxygen
and CuII (Shepard and Dooley, 2015). The copper atom in PrAO has a pentacoordinate state and is bonded to three histidines and to a pair of water molecules that
stabilize the copper ion in the ‘off” state (discussed in greater detail in Section 1.5).
There are four domains present in PrAO designated D1, D2, D3 and D4, where D4 is
known to contain the active site (Shepard and Dooley, 2015).

1.2.2 Inter species variation in PrAO active site ligand access.
The crystal structures solved for PrAO indicate it has a wide-mouthed funnel leading
to the active site entrance (Fig. 1.3). Variations in structure between PrAO species,
such as between human and bovine enzymes, are found within the funnel and at the
active site entrance which leads to widening, or narrowing, of the funnel at the active
site entrance thereby giving rise to variations in ligand access (see Table 1.1)

Two long hairpins or “arms” join the two PrAO monomers forming the dimer unit.
One of these arms stretches along the surface of the enzyme to the funnel entrance and
may play a role in determining substrate/inhibitor specificity. The residues at the end
of the arm differ between human and bovine forms (Yraola et al., 2006). PrAO is
known to be glycosylated at several sites. It is possible that carbohydrates attached to
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PrAO may also serve to regulate ligand access. Finally, the funnel wall leading to the
active site is lined with hydrophobic and aromatic amino side chains which potentially
form bonds to an incoming ligand which can further influence active site access and
substrate specificity (Holt et al., 2008a; Jakobsson et al., 2005).

Bovine PrAO has a somewhat more open active site entrance than the human enzyme
with the funnel being less obstructed thus permitting greater ligand access to the active
site. (Jakobsson et al., 2005). A specific leucine residue acts as an active site “gate”
(Leu469 in human and Leu468 in bovine) to control ligand access at the active site
entrance (Yraola et al., 2006). Notwithstanding these observations the active site of
both human and bovine enzymes can accommodate substrates as large as benzylamine
and phenethylamine and they show similar inhibitor sensitives.
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Table 1.1: A selection of residue variations between bovine and human PrAO and conserved
active site residues. These residues are located in the vicinity of the funnel entrance leading
to the active site. (Holt et al., 2008a; Jakobsson et al., 2005; Yraola et al., 2006).

Location

Bovine Residue

Human Residue

Comparison

Funnel brim

Leu172

Phe173

Both hydrophobic

Arg393

Phe larger due to phenyl
group
Tyr Hydrophobic

Tyr394

Arg Positive Charge,
larger residue
Both hydrophobic

Asn211

Thr212

Tyr having an additional
hydroxyl group
Both polar

Pro237

Phe238

Asn being larger
Both hydrophobic

Funnel

Tyr392

Phe393

Funnel base

Pro is a cyclic amide

Tyr238

Hairpin (arm) tip,
near active site
entrance

Phe 446

Leu 447

Active site entrance

Leu468

Phe239

Phe larger due to phenyl
group
Both hydrophobic

Leu 447

Tyr has an additional
hydroxyl group
Both hydrophobic

Tyr 448

Phe larger due to phenyl
group
Both hydrophobic

Leu469

Tyr larger due to phenyl
group
Leu468 acting as a
“gate”
Leu469 acting as a
“gate”

Conserved Active
Site Residues
Between Both
Species

TPQ, His520, His522, His684, Asp386, Tyr372,
Tyr384, Phe389, Tyr394 and Leu468
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1.3

Physiological role of PrAO

The physiological role of PrAO is confusing since its best substrate, benzylamine, is
a non-physiological compound. Indeed, identifying physiological substrates for this
enzyme has proven difficult. The main catalytic function of PrAO is thought to be the
breakdown and removal of primary amines in the body. However, in view of the
observation that the aldehydes derived from amines such as aminoacetone and
methylamine (the best physiological substrates) may be more toxic than their parent
amines this role is unclear (Hernandez et al., 2006b). In its role as a vascular adhesion
protein PrAO binds human sialic acid-binding immunoglobulin-like lectin-10 (Siglec10) which acts as a substrate. The amino group on siglec-10 that gives rise to this
activity has not been identified (Elovaara et al., 2016).

In previous studies, it has been shown that PrAO is expressed in high concentrations
in smooth muscle, endothelial and adipose cells, suggesting its involvement in
important functions at these locations (Enzsoly et al., 2013). Hydrogen peroxide
(H2O2), when produced by PrAO, is known to act as an insulin mimetic having the
ability to stimulate the uptake of glucose from blood plasma by recruiting glucose
transporter type 4 (GLUT 4) and GLUT 1 transporters extracellularly (McDonald et
al., 2007).
Another highly important physiological function of PrAO is its ability to act as a
vascular adhesion protein (Fig. 1.4). This function was discovered in 1998, when a
Finnish group cloned a gene coding for the protein they called: vascular adhesion
protein 1 (VAP-1) (Smith et al., 1998). They were surprised when they found that their
protein had already been cloned under the name human placental amine oxidase
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(HPAO) (Zhang and McIntire, 1996). This important finding greatly stimulated
interest in PrAO (Luo et al., 2013).

Fig. 1.4: Image depicting VAP-1 (PrAO) mediated leukocyte extravasation. Extravasion refers to the
crossing of the endothelial cell wall to a site of insult via tethering, rolling and tight binding to VAP1. Leukocytes with their attached ligand or receptor are shown binding or “tethering” to VAP-1 on the
vascular endothelium. After the leukocytes bind to VAP1 they roll along the endothelium before
establishing a tight binding complex. The formation of the complex allows the extravasion of
leukocytes to a site of injury in a tissue (O'Sullivan et al., 2004).

PrAO is known to be involved in vascular smooth muscle cell differentiation,
influencing extracellular matrix composition and the regulation of vascular tone
(Olivieri et al., 2011). The cellular matrix composition and maturation of collagen and
elastin was disrupted in rat models when PrAO was inhibited with semicarbazide. This
effect was probably due to PrAO-derived formaldehyde protein cross-linking
(Mercader et al., 2011). Elastin structure maturation tests performed on rat aorta
revealed that PrAO inhibition reduced mature elastin levels and compromised
collagen elastin matrices, suggesting PrAO involvement in these physiological
processes. PrAO is found at high amounts on fat cell surfaces and has been shown to
be directly involved in adipose cell maturation and differentiation (Mercier et al.,
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2003). Murine studies demonstrated a decrease in fat cell size and weight gain in mice
when PrAO was inhibited with semicarbazide (Mercader et al., 2011).

While PrAO is predominantly found either membrane-bound or free floating in plasma
it can also be found intra-cellularly in GLUT4-containing intracellular vesicles in
adipocytes. Amine oxidase substrates such as benzylamine and methylamine have
been shown to stimulate glucose uptake in rat adipocytes by increasing the recruitment
of the glucose transporter GLUT4 from vesicles within the cell to the cell surface via
the phosphatidylinositol 3-kinase (PI3K) pathway. It is thought that PrAO can mimic
the adipogenic effect of insulin in cultured pre-adipocytes through the production of
H2O2 during amine oxidation. Furthermore, it has been suggested that PrAO not only
represents a novel late marker of adipogenesis, but could also be directly involved in
the triggering of terminal adipocyte differentiation (Enrique-Tarancon et al., 1998;
Göktürk et al., 2003; McDonald et al., 2007).
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1.4

PrAO catalysed Oxidation of Amines

The oxidation reaction that converts primary amines into their respective aldehyde,
ammonia and hydrogen peroxide products by PrAO is carried out at the active site
involving the TPQ cofactor and CuII (Autio et al., 2013). A ping-pong kinetic
mechanism was proposed for this reaction (Fig. 1.5). Catalysis proceeds by, firstly, a
reduction of TPQ to release an aldehyde product and secondly, an oxidative cycle
releasing H2O2 and ammonia (Largeron, 2011). In brief, this reaction occurs when
TPQ in its oxidised state reacts with a primary amine substrate producing a Schiff
base. Subsequently, a quinolaldimine “product schiff base” is formed whose formation
is facilitated by an α-carbon extraction from a conserved aspartate. The aldehyde
product is then released via hydrolysis simultaneously forming the reduced
aminoquinol (Fig. 1.5, Scheme 1) thus completing the first half of the reaction.

In the second part of the reaction TPQ is re-oxidised by O2. There is some controversy
over the mechanistic details of the oxidative half reactions and Figure 1.5 shows two
possibilities.
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Scheme 1. Proposed reductive half-reaction mechanism

Scheme 2. Alternative pathways for the oxidative half-reaction.

Fig. 1.5: Reaction mechanism for the oxidative deamination of a primary amine catalysed by PrAO.
In this scheme TPQox is the oxidised form of the cofactor and TPQAMQ is the reduced amino quinol
form. Scheme 1 shows the reductive half reaction where the primary amine forms a Schiff base with
the cofactor. After protonation a product Schiff base is formed which is hydrolysed to release the
aldehyde product. The cofactor at this stage is in the aminoquinol form which is oxidised in the second
oxidative half reaction. Scheme 2 shows two alternative pathways proposed for the oxidative half
reaction. Both pathways lead to the formation of an iminoquinone intermediate which is hydrolysed
to produce ammonia and H2O2 (Shepard and Dooley, 2015).

Despite mechanistic uncertainties both possibilities lead to formation of a Copper
(CuII)−hydroperoxide, iminoquinone intermediate. Finally, this intermediate is
hydrolysed to release ammonia and hydrogen peroxide regenerating the TPQ
cofactor (TPQox in Fig. 1.5; Scheme 2) (Shepard and Dooley, 2015).
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An equilibrium state occurs between copper and TPQ in the active site where the
copper atom transitions between an ‘on’ and ‘off’ position (Fig. 1.6). A reaction with
an amine substrate occurs only when the Cu is in the ‘off’ (meaning not attached to
TPQ) position whereby it is bonded to three histidines and two water molecules. In
the ‘on’ position, the Cu is bound directly to a hydroxyl group of the TPQ cofactor
preventing a nucleophilic attack on TPQ (Klema and Wilmot, 2012).
B

A

Fig. 1.6: TPQ represented in an equilibrium state in both the ‘off’ positions. The off position is depicted
in A and the ‘on’ position in B where the ‘off’ state involves Cu bound to three histidines and two
water molecules. The ‘on’ state involves TPQ replacing the water molecules and binding to Cu
(Shepard and Dooley, 2015). Only the off” position can catalyse amine oxidation.

1.5

PrAO Substrates

PrAO substrates can include long or short aliphatic and arylalkylamines (Kinemuchi
et al., 2004b). Aminoacetone, methylamine and allyamine are well-characterised
aliphatic substrates. Benzylamine, tyramine and spermidine (see Figure 1.7) are some
of the more well-known substrates. The main physiological substrates are thought to
be methylamine and aminoacetone (Hernandez et al., 2006a).
18

Substrate specificity can overlap between Cu/TPQ and flavin-containing amine
oxidase species (see Table 1.2). For example, both PrAO and MAO can use substrates
such as dopamine, tyramine and benzylamine. While there is no clear physiological
reason for these overlaps, studies have shown that if MAO is suppressed, PrAO can
provide an alternative pathway for metabolism of these amines (Yraola et al., 2009).

Table 1.2: Common substrates between members of the amine oxidase family. The members
are: diamine oxidase (DAO), monoamine oxidase (MAO), lysyl oxidase (LOX), polyamine
oxidase (PAO) and primary amine oxidase (PrAO) (Floris and Mondovi, 2009; Hernandez et
al., 2006a; Yraola et al., 2009).

Substrates

PrAO

DAO

LOX

MAO

Copper containing

PAO

Flavin containing

Allylamine

Yes

-

-

No

No

Aminoacetone

Yes

-

-

No

No

Benzylamine

Yes

Yes/low

Yes

Yes

No

Cadaverine

+/-

Yes

Yes

No

No

Dopamine

Yes

Yes

-

Yes

No

Histamine

+/-

Yes

+/-

No

No

L-lysine

+/-

No

+/-

No

No

Noradrenaline

+/-

+/-

-

Yes

No

Methylamine

Yes

No

-

No

No

Putrescine

+/-

Yes

-

No

No

Spermidine

Yes

Yes

-

No

No

Tryptamine

+/-

No

-

Yes

No

Tyramine

Yes

-

-

Yes

No

Notes: +/- some studies show catalysis and some not. The dash,-, indicates no data available.

1.5.1 Sources of Amines
PrAO substrates can be ingested directly through the diet; for example, dopamine from
fruit, histamine from fish and cheese and 2-phenylethylamine from chocolate and meat
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(Olivieri et al., 2011). In addition, amine substrates such as allylamine, a compound
used in the manufacture of vulcanized rubber, can enter the body through the
environment. Certain aromatic amines can be absorbed via tobacco smoke (Olivieri et
al., 2011). Although PrAO breaks down potentially toxic amines, sometimes the
products formed can be more toxic than the amine substrate itself, i.e. methylamine is
deaminated to the more toxic and reactive species formaldehyde (Section 1.8; Sun et
al., 2014).

Fig. 1.7. Range of known PrAO substrates Images taken from ChemSpider
(http://www.chemspider.com/Chemical-Structure).
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1.6

PrAO and Disease

High PrAO catalytic activity is associated with the progression of a variety of disease
states from obesity and vascular disease to kidney disease (Wong et al., 2013;Mátyus
et al., 2013). PrAO substrates such as methylamine, aminoacetone and allyamine can
be oxidised into even more reactive and toxic products, such as formaldehyde,
methylglyoxal and acroelin, respectively. These highly reactive species can cause
protein crosslinking, oxidative stress and the formation of Advanced Glycation End
(AGE) products (Fig. 1.7). The reaction product accompanying amine oxidation,
hydrogen peroxide, can also be transformed to a reactive hydroxyl radical, further
increasing cell damage (Mercier, 2009; Wong et al., 2013).

Fig. 1.8: Diagram illustrating the relationship between PrAO and disease. PrAO is associated with
disease (e.g. kidney fibrosis). Repeated initial insult (hyperglycemia, inflammation, toxins, endothelial
stress, uremia, etc.) leads to increased production of PrAO substrates. It also stimulates leucocyte
transmigration which leads to further inflammatory response. The aldehydes produced by PrAO catalysed amine oxidation cause vascular damage directly by cytotoxic insult and indirectly by
formation of advanced glycosylation end products (AGE’s). This damage causes the upregulation of
pro-inflammatory and pro-fibrinogenic cytokines in addition to promoting local tissue hypoxia, all of
which contribute to tissue damage (Wong et al., 2013).
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1.6.1 Elevated PrAO Activity and Disease
For some conditions the state of disease advancement is often correlated with an
increase in PrAO activity as evidenced by diabetes (Januszewski et al., 2014). A
higher concentration of PrAO in turn leads to a higher turnover of reactive products,
for example formaldehyde, methylglyoxal and acroelin, which may directly increase
Advanced Glycation End product formation and exacerbate diabetic complications of
vascular injury and capillary cell damage (Nunes et al., 2010) as well as heart disease
(Marinho et al., 2010).

Alzheimer’s disease, stroke and multiple sclerosis are also associated with elevated
levels of PrAO causing the formation of reactive species and the associated
inflammation mediated by VAP-1 (Alferova et al., 2010; Salter-Cid et al., 2012;
Valente et al., 2012). Alzheimer’s disease (AD) is a progressive neurological disorder
of the central nervous system (CNS), which leads to dementia and cognitive
impairment (Dubois et al., 2014). One of the major pathological features in the
progression of AD is cerebral amyloid angiopathy (CAA), which is caused by the
deposition of β-amyloid (Ab) plaques. Overexpression of PrAO has been found in
areas of β-amyloid plaque deposits (Chen et al., 2007b; Unzeta et al., 2007). Indeed,
elevated levels of aldehydes are associated with Alzheimer’s disease and might play a
role in β-amyloid aggregation. Chen et al investigated the link between elevated
endogenous aldehydes, either from lipid peroxidation or from amine deamination, and
the formation of β-amyloid plaques. Their findings support the involvement of
endogenous aldehydes in amyloid deposition related to Alzheimer’s Disease. When
PrAO was inhibited in the presence of methylamine, it led to a marked decrease of βamyloid plaque aggregation by up to 80% (Chen et al., 2007a)
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Type I and type II diabetes have been associated with high levels of PrAO in blood
plasma (Boomsma et al., 2005; Göktürk et al., 2003). Studies have shown PrAO
oxidation products, formaldehyde and methylglyoxal, can form AGEs. These
aldehydes along with H2O2 produced by PrAO cause crosslinking of proteins and
exacerbate diabetic complications such as retinopathy, neuropathy, nephropathy and
atherosclerosis (Li et al., 2016). In vivo studies comparing patients with a known
history of diabetes and vascular complications with a control group of similar age and
gender revealed a correlation with high PrAO levels and the state of progression of
this disease. Those with diabetic conditions had above average PrAO blood plasma
levels when compared to healthy individuals (Januszewski et al., 2014).

1.6.2 VAP-1 and Inflammation
As previously disscussed, the membrane bound form of PrAO (VAP-1) has been
shown to have an important role in the adhesion and recruitment of leukocytes to sites
of inflammtion. This function has shown to be problematic when overexpressed at
sites where VAP-1 is predominately found such as vascular and adipose tissue
(Göktürk et al., 2003). Silvola et al., 2016 showed that VAP-1 was expressed on
endothelial cells, where inflamed atherosclerotic lesions were present. Furthermore,
they demonstrated that the inhibition of VAP-1 activity decreased the density of
macrophages in inflamed atherosclerotic plaques in mice. Their findings led these
workers to suggest VAP-1 inhibition as a therapeutic approach in the treatment of
atherosclerosis.

Studies indicated that VAP-1 could mediate inflammation leading to tumor initiation
and progression in a mouse model (Ferjančič et al., 2013; Salmi and Jalkanen, 2011).
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Their studies showed that VAP-1 deficient mice had less efficient leukocyteendothelial cell contacts resulting in reduced leukocyte recruitment and inflammation.
In addition, Salmi and Jalkanen found that, in VAP-1-deficient mice, cancers such as
melanoma spread more slowly than in wild type. This clearly points to a role for VAP1 (PrAO) in regulating the spread of cancer. Similar findings were obtained with wild
type mice where small molecule inhibitors of VAP-1 were employed showing a strong
link between VAP-1 and cancer progression (Salmi and Jalkanen, 2011).

1.7

Inhibitors of PrAO

A number of attempts have been made to develop specific, potent inhibitors of PrAO
as therapeutics. It has proven challenging to find an inhibitor with the required
specificity and potency due to similarities in active site structure to other AOs (see
Section 1.5, Table 1.2). It is important that an inhibitor of PrAO does not overlap in
specificity and inhibit other amine oxidases and is nontoxic and readily absorbed.
Enzyme inhibitors can be chemically and structurally similar to their substrate
counterparts (see section 1.6) when bound within the active site such as with the
substrate benzylamine and the inhibitor Phenylhydrazine. PrAO inhibitors can be
classified by structure or functional groups into a few categories: hydrazines,
arylalkylamines, propenyl- and propargylamines, oxazolidinones, and haloalkylamine
derivatives. A selection of known inhibitors of PrAO include hydrazine compounds,
i.e.

semicarbazide

and

aminoguanidine,

arylalkylamine

compounds,

i.e.

phenylhydrazine, and mexiletine and haloalkylamines such as 2-bromoethylamine are
shown in Table 1.3, (Foot et al., 2013).
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Table

1.3:

Inhibitors

of

PrAO.

Images

taken

from

PubChem

(https://www.ncbi.nlm.nih.gov/pccompound).

Inhibitor Class

Example

Hydrazine

Semicarbazide

Arylalkylamine

Phenylhydrazine

Propenylpropargylamines

Mexiletine

Oxazolidinone

Almoxatone

Haloalkylamine

2-bromoethylamine

Structure

For PrAO, inhibition can be achieved in the active site via reaction with TPQ or by
steric blockage of the active site entrance or funnel (see Jakobsson et al., 2005).
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1.7.1 Inhibition of PrAO
A selection of inhibitors of PrAO is discussed in detail below. IC50, Ki data and
patterns of inhibition are provided where available. Hydroxyurea (hydroxycarbamide)
(Table 1.4), a hydroxamic acid derivative used as an anti-cancer drug and for sickle
cell treatment was shown to be an inhibitor of PrAO (Liu et al., 2010). These workers
found that hydroxyurea was a competitive inhibitor of bovine PrAO using
benzylamine as substrate and a Ki value 1.835µM was estimated. In an extension of
this work these workers identified galacturonic acid hydroxamate as a noncompetitive inhibitor of bovine plasma PrAO (Liu et al., 2011).

Table 1.4: Overview of hydroxamic based inhibitors of PrAO. Ki, IC50 and patterns of
inhibition are given where available for each inhibitor that was screened against bovine PrAO.
Images taken from PubChem https://www.ncbi.nlm.nih.gov/pccompound).
Inhibitor

IC50

Hydroxyurea 6.33µM

Ki
1.835µM

Pattern of
Inhibition
Competitive

Galacturonic
acid
hydroxamate

41µM

Not given

Non-competitive

L-lysine

37.4µM

Not given

Un-competitive
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Structure

Since PrAO has been reported to oxidize peptides containing lysine the possibility that
cell-surface lysyl reasidues might be the PrAO/VAP-1 recognition sites was
considered. Olivieri et al. (2010) reported that the free amino acid L-lysine acted as an
H2O2-dependent inhibitor of beef plasma PrAO.

1.8

Dietary components in Health and disease

Previous work in these laboratories explored the role of dietary components in health
and disease. The protective effect of plant food sources against chronic diseases are
often attributed to bioactive non-nutrients called phytochemicals (Vayalil, 2012).
Phytochemicals are secondary plant metabolites that are not essential nutrients but
known to have protective or disease preventive properties. In plants they can play a
substantial role in the prevention of microbial, insecticidal or herbivorous attack (Naz
et al., 2013).

Interest in phytochemicals is growing in the research community (Monteiro et al.,
2016). One such family of phytochemicals, methylxanthines, have been the subject of
much research over the years for their ability to block A2A adenosine receptors thereby
acting as psychoactive stimulants and potential therapeutics for neurodegenerative
diseases (Daly, 2007). The effect of methylxanthines on neurodegenerative diseases
(Oñatibia-Astibia et al., 2017), cardiovascular disease (Khan et al., 2012),
inflammation, (Frost-Meyer and Logomarsino, 2012) and cancer (Sang et al., 2013)
are active areas of current research.

Another family of phytochemicals, polyphenols, are also being studied for their health
benefits associated with cancer, diabetes, inflammation, heart disease, Parkinson’s
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disease and obesity (Chang et al., 2015; González-Castejón and Rodriguez-Casado,
2011).

Organic nutrients such as amino acids (AAs) and vitamins are also being studied for
their health benefits. AAs are being studied for their potential in prevention and
treatment of obesity, diabetes, and cardiovascular disorders, intestinal and
neurological dysfunction, and infectious disease (including viral infections) (Wu,
2013; Wu, 2014).

Micronutrients like vitamins are known to be of interest in the prevention of a number
of diseases such as migraine, anaemia, cancer, hyperglycemia, hypertension, diabetes
mellitus, and oxidative stress. (Eitenmiller et al., 2016; Takata et al., 2013; Thakur et
al., 2017). The following sections will consider some of the more prominent
phytochemicals in greater detail.

1.8.1 Caffeine and Related Methylxanthines
Methylxanthines are secondary plant metabolites formed from purine nucleotides.
They are classed as purine alkaloids and are ubiquitously found in plants. High
concentrations of methylxanthines are found in Coffea arabica (coffee), Camellia
sinensis (tea) and Theobroma cacao (cacao). The two most common and well-studied
methylxanthines are caffeine and theobromine (Fig. 1.8). Other types of
methylxanthine’s commonly found in food include theophylline, paraxanthine and 7,
methylxanthine (Ashihara and Crozier, 1999).
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Fig. 1.9: Selection of methylxanthine structures. Images taken from PubChem
(https://www.ncbi.nlm.nih.gov/pccompound).

Caffeine (1,3,7-trimethylxanthine) is a white crystalline alkaloid, which is found in
the beans, fruits and leaves of over 60 plant varieties. However, the primary dietary
sources are roasted coffee beans and tea leaves (Barone and Roberts, 1996). Caffeine
and related xanthine analogues are known to have physiological effects on adenosine
receptors, phosphodiesterases and calcium release channels and are thought to be
potential therapeutics for Alzheimer’s disease, diabetes and cancer (Daly, 2007).
Olivieri and Tipton (2011) noted caffeine to non-competitively inhibit Bovine PrAO
with a Ki value of 1.0 mM. (Olivieri and Tipton, 2011). Other methylxanthines closely
related to caffeine are theophylline, paraxanthine, 7,methylxanthine and theobromine,
These molecules differ from caffeine by one, or more, methyl groups at either position
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1, 2 or 3 around the xanthine structure (Fig. 1.8) and are also found naturally in the
diet.
Theobromine is most abundant in cocoa beans with a dry weight composition of 2.7%
(Ashihara and Crozier, 1999). The reported health benefits of theobromine include
anticancer, anti-inflammatory and cardiovascular protection without the unwanted
stimulatory side effects such as insomnia, high heart rate and nervousness that can be
associated with high caffeine intake (Martínez-Pinilla et al., 2015;Sugimoto et al.,
2014).
Theobromine although structurally similar to caffeine has a number of chemical and
physiological differences. For instance, theobromine has a calming sleep inducing
effect on the body while caffeine is known for its stimulant properties (Khan et al.,
2017). Interestingly, a study with human molars showed remarkable protection of the
enamel surface upon application of 200 mg/L of theobromine solution. The effect was
not observed with other methylxanthines (Kargul et al., 2012).
The half-life of theobromine in humans is much higher than for caffeine. Caffeine is
highly water soluble, peaks in the blood 30– 40 min after ingestion, and has a half-life
of 2.5–5 h, while theobromine is less water soluble, attains peak blood concentrations
2–3 h after ingestion and has an estimated half-life of 7– 12 h (Baggott et al., 2013).
Theobromine consumption is generally safe for humans but for dogs it is highly toxic.
The half-life of theobromine in dogs is 17.5 h. Theobromine median lethal dose (LD50)
is about 1000 mg/ kg in humans and in dogs 300 mg/kg (Ahlawat et al., 2014). The
three main metabolites of caffeine are paraxanthine (84%) theophylline (4%) and
theobromine (12%) (Santos et al., 2015). The positive health benefits associated with
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caffeine could be partly due to the products of its metabolism such as theobromine and
theophylline (Martínez-Pinilla et al., 2015).
1.8.2 Green Tea
Tea from the Camellia sinensis plant is a popular drink that is consumed worldwide
and is specifically noted for its beneficial health effects. These health benefits are
attributed to the leaf polyphenols. These flavonoids account for the majority of green
tea polyphenols (GTPs) (Steinmann et al., 2013; Table 1.5).

Table 1.5: The chemical dry composition of green tea (Sinija and Mishra, 2008)

Polyphenols

30%

Proteins

15 - 20%

Fibre

26%

Carbohydrates

5 - 7%

Lipids

7%

Minerals and trace elements

5%

Amino acids

1 - 4%

Pigments

2%

The steaming of tea leaves during processing inactivates the enzyme (Polyphenol
Oxidase, EC. 1.14.18.1). This enzyme is responsible for the breakdown of polyphenols
and colour pigments and its inactivation gives the tea its green colour - in contrast to
enzymatically fermented black tea (Cabrera et al., 2010). Many health benefits have
been associated with green tea and numerous studies carried out to investigate these
claims. Health benefits are thought to include the prevention of cancer, diabetes,
inflammation, heart disease, Parkinson’s disease and obesity (Chacko et al., 2010;
Hara, 2001; Schneider and Segre, 2009; Sinija and Mishra, 2008). See Fig. 1.10.
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Fig. 1.10. An overview of Green Tea Polyphenols health benefits in a range of diseases. Arrows
indicate an increase or decrease in effect.

1.8.2.1 Polyphenols
Polyphenols are secondary metabolites found in plants that have been reported to act
as antioxidants, anti-allergic, anti-inflammatory, anticancer, antihypertensive, and
antimicrobial agents in human health (Daglia, 2012). Polyphenols can be broken into
subclasses such as phenolic acids, lignans, stillbenes, isoflavones and flavonoids.
Flavonoids can be further subdivided into flavanols, flavonols, anthocyanins,
flavones, flavanones and flavanonols. For instance, flavonols include quercetin and
kaempferol while flavanols include the catechins; Epigallocatechin gallate (EGCG)
and Epicatechin gallate (ECG) (González-Castejón and Rodriguez-Casado, 2011).

The most abundant type of polyphenols found in green tea are flavonoids of which
catechins are the most abundant (Fig. 1.10). The four most significant catechins are
epigallocatechin gallate (59%), epigallocatechin (19%), epicatechin gallate (13.6%)
and epicatechin (6.4%) (Steinmann et al., 2013).
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Polyphenols may be useful in ameliorating the deleterious effects associated with
obesity. Cellular studies demonstrated that dietary polyphenols reduce viability of
adipocytes and proliferation of pre-adipocytes, they suppress adipocyte differentiation
and triglyceride accumulation, stimulate lipolysis and fatty acid β-oxidation and
reduce inflammation. Animal studies strongly suggest that commonly consumed
polyphenols have a pronounced effect on obesity. Their administration gives rise to
lower body weight, fat mass, and triglycerides. They seem to act through enhancing
energy expenditure and fat utilization, and by modulating glucose hemostasis. (Wang
et al., 2014a). Epigallocatechin gallate (EGCG) has been the compound most widely
explored (Chen et al., 2011;Wang et al., 2014a).

Fig. 1.11. Chemical structures of the four most abundant polyphenols found in green tea. Images
acquired from (https://www.ncbi.nlm.nih.gov/pccompound).
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1.8.2.2 Green Tea Polyphenols in Health
Studies have shown that GTPs, particularly EGCG, contribute to the prevention of
cancer. (Chen et al., 2011) have shown that EGCG protects DNA from methylation
and mutation which can be a first step in the formation of cancer. GTPs can prevent
oncogene expression of cancer-causing genes, promoting expression of p53 and p27
thus inducing apoptosis. Furthermore, GTPs inhibit proteasome activity, which can
prevent the degradation of regulatory cell proteins that can also lead to cancer. In vivo
studies by Chacko and colleagues (2010), demonstrated that the administration of
GTPs lowered plasma glucose levels in diabetic rat models at a dose of GTPs at 100
mg kg-1 and that EGCG exhibited an insulin mimic effect, lowering glucose levels by
44% whilst concomitantly increasing tyrosine phosphorylation of the insulin receptor
(Chacko et al., 2010).

Inflammation studies with EGCG, the principal polyphenol of Green Tea, at
100 mmol/L showed 50% inhibition of TNFα production in a dose-dependent fashion
in a macrophage cell line. EGCG also showed 30–40% inhibition at 100 mmol/L of
TNFα mRNA expression and nuclear NF-ΚB–binding activity (Guo et al., 2009; Yang
et al., 1998) which could be a factor for GTPs and associated decrease in
inflammation.

1.8.3 Amino Acids
Amino Acids are involved in protein formation and cell signaling and are regulators
of gene expression and are also precursors of many hormones (Wu, 2009). Free AAs
are readily available through the diet, have primary amine groups and can therefore
serve as potential modulators of PrAO.
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In the present study, research interest in AAs and PrAO modulation was spurred by
previous findings in these laboratories (Olivieri et al., 2007) which showed L-lysine
binding to PrAO. L-lysine, showed inhibition of VAP-1/PrAO and gave an apparent
Ki value 166 ± 48 µM. L-lysine could not inhibit directly, but required the presence of
H2O2 to have an inhibitory effect (Olivieri et al., 2007).

1.8.4 Vitamins and Health Benefits
Vitamins A, C, D, K and E have all been examined as agents in cancer prevention
(Block, 1991; Klein et al., 2003; Lotan, 1980; Ness et al., 2015). Many of the exact
mechanisms of actions with regards to these health benefits have not been fully
characterised. For example, studies with vitamin B supplements demonstrated a
positive effect with Alzheimer’s patients (Dangour et al., 2010), although the exact
mechanism was not fully elucidated.

An area of research where vitamins have been shown to inhibit enzymes was reported
with the inhibition of lactoperoxidase, an enzyme that functions as a bactericide and
uses hydrogen peroxide as an oxidising agent (see Table 1.6). Vitamins reported to
have an inhibitory effect on this enzyme include vitamin C, K3 and folic acid.
Reported inhibition mechanism for all three vitamins showed a competitive type of
inhibition mechanism, Sisecioglu et al. (2010).
Table 1.6: Selection of vitamins that have a modulating effect on lactoperoxidase,
(Sisecioglu et al. 2010).
Inhibitor
IC50 Values
Ki Values
Folic Acid

0.0925 mM

0.0218 ± 0.0019 mM

Vitamin K3

0.025 mM

0.0107 ± 0.0044 mM

Vitamin C

2.03 µM

0.508 ± 0.257 µM
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Fernando and Soysa (2015) examined the oxidant scavenging activity of Vitamin C
and related compounds. The test method employed 4-aminoantipyrine, in the presence
of horseradish peroxidase (HRP), to produce a pink coloured quinoneimine dye. This
is the same method used to detect activity rates of PrAO in the visible region through
conjugation of H2O2 to produce the quinoneimine dye (see Section 2.5.1). False
inhibition results can be observed if compounds that have antioxidant properties are
being screened as potential inhibitors, as happened with the reported inhibition by
Sisecioglu et al. (2010), using vitamin C, K3 and folic acid. These compounds are all
antioxidants that caused interference where the assay detection method involves
hydrogen peroxide as the oxidising agent. Careful controls must be set in place for
ligands screened with PrAO, to account for such antioxidant interactions.

1.9

Computational Modelling

Traditionally, laboratory-based methods were used to discover novel leads in drug
discovery via strategies such as high-throughput screening. Some disadvantages of
this approach include high cost, the use of significant resources and frequent low hit
rates (Williams et al., 2015). The completion of the human genome project has
permitted drug targets to be identified and studied via computational approaches. This,
coupled with recent advances in biological structure analysis, such as X-ray
crystallography and nuclear magnetic resonance (NMR) structure determination has
opened new avenues for analysing and predicting ligand-target binding interactions
(Voet et al., 2014). Moreover, advances in computing power and software have
resulted in faster and cheaper in-silico methods becoming available in early-stage drug
discovery. Such in-silico methods are growing in popularity (Cosconati et al., 2010)
and can be used to predict the interactions of a ligand with a protein binding site as
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well as estimating their binding strengths or relative affinity (Yuriev and Ramsland,
2013).

There are two main approaches to computational modelling: ligand based drug design
(LBDD) and structure based drug design (SBDD) modelling. Ligand based modelling
is applied when the molecular target is not known or fully understood but experimental
binding/functional data is available for given ligands with a certain protein or
molecular target. A “training set” of ligands that are known to bind or interact with a
molecular target are employed where similar features among these ligands such as
size, charge and functional groups, aid in describing the structure-activity
relationships (SARs) (Kaserer et al., 2015). In the structure-based approach the
macromolecule structure or target complexes are known and are obtained either from
computational homology modelling, experimental nuclear magnetic resonance
(NMR) data or X-ray crystallography. The main purpose of SBDD techniques such as
molecular docking is to design or analyse ligands with specific electrostatic and
stereochemical attributes to achieve high receptor binding affinity. These compounds
can then be used for developing potential therapeutics (Ferreira et al., 2015).

1.9.1 Molecular Docking
Molecular docking, which is an SBDD approach, is a computational method that
predicts the binding of a small a molecule or ligand to a known macromolecule
receptor-binding site. There are many docking tools in use today such as Autodock,
GOLD, FlexX or ICM (see Table 1.7), which can generate various poses of a ligand
and receptor and employ mathematical algorithms such as Monte Carlo, genetic
algorithms or fragment-based algorithms to select the best interacting binding poses
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(see Table. 1.7) (Azam and Abbasi, 2013). Autodock and GOLD employ a genetic
algorithm based on an iterative process. They begin by docking the ligand into various
conformational spaces allowing the optimum binding conformations to go forward to
another round of modelling. In the first round the software eliminates energetically
unfavorable conformations. DOCK and FlexX employ an incremental reconstruction
algorithm where fragments are identified, docked into a receptor until the completed
ligand is added step by step: only the highest scoring fragments progress to subsequent
rounds of modelling (Agarwal and Mehrotra, 2016).

To achieve virtual docking of a ligand to a binding site a target structure is
computationally modelled or experimentally solved, for example, by X-ray
crystallography. The ligand and target structures are prepared by assigning tautomeric,
stereoisomeric and protonation states. Docking generally gives rise to two main
interrelated outcomes where:
i. A series of binding conformations or interactions of a given ligand (with
tautomer/stereoisomers/protonation states enumerated) with a protein are
generated
ii. Docking poses are ranked in order of predicted binding affinity via an algorithm
scoring function.

The scoring function can be either empirical, knowledge based or employ force field
computation (Liu and Wang, 2015). Empirical scoring functions have been developed
to reproduce experimental binding affinity data, knowledge-based functions have
been developed based on the statistical analysis of interacting atom pairs from known
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protein–ligand complexes with available three-dimensional structures (Cheng et al.,
2012).

Force field, which is the scoring function used in this study, utilises a probe atom,
typically carbon, to estimate the free binding energy of a target macromolecule at a
certain grid point location. The force field calculation accounts for the bonded (bond,
angle and dihedral) and non-bonded (Van der Waals and electrostatic forces)
interactions. A ranked list is then provided of the lowest predicted binding energy
scores (Hill and Reilly, 2015).

Attempts at computationally docking small ligands to PrAO have been reported. A
library of 48 potential compounds that could potentially bind to PrAO were reduced
to the most favorable 20, based on the best scores achieved for each compound. Of
those 20 lead compounds 3 newly discovered hits or substrates were found. These
hits resulted in a good correlation between docking calculations and experimental data
when these substrates were tested for activity with PrAO (Yraola et al., 2006).

Another study used Glide docking software where PrAO and MAO were both
computationally docked and subsequently assayed with a range of phenolic
compounds (quercetin, resveratrol, pterostilbene and caffeic acid). Experimental data
showed that none of the phenolic compounds inhibited PrAO and only quercetin and
resveratrol had any effect on MAO (Carpéné et al., 2016).
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Table 1.7: A selection of docking tools and their respective algorithms. The table highlights
the pros and cons of each type (Chaudhary and Mishra, 2015; Morris et al., 2009).
Docking Tool
AutoDock

Algorithm
Genetic algorithm,
Lamarckian genetic
algorithm, Simulated
annealing

Scoring
Function
Auto Dock
(force-field
methods)

Pros

Cons

Targeted flexible
docking

Target protein too
flexible,
Flexible ligands

Gold

Genetic algorithm

Gold score,
Chem score,
User defined,

Small binding sites,
Opened cavities, Small
hydrophobic ligand

Flexible ligands, Highly
polar ligands,
Very flexible ligands

FlexX

Incremental construction

FlexX score,
PLP

Small binding sites,
Opened cavities,
Small hydrophobic
ligands,
Small binding sites

Highly polar ligands,
Flexible ligands

Glide

Monte Carlo

Glide Score,
Glide Comp

Flexible ligands, Small
hydrophobic ligands

Ranking very polar
ligands,
Slow speeds

1.9.2 Molecular Docking with AutoDock Tools
For this study, AutoDock Tools V1.5.6 was used to simulate bindings of ligands to
PrAO. AutoDock has been in use since 1990 (Hsieh et al., 2016) and over the years
has been an effective tool in predicting bound conformations as well as binding
energies for ligands with a chosen molecular target (Jung et al., 2016; Morris et al.,
2009; Wang et al., 2014b).
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The AMBER force field scoring function is used by AutoDock tools
(http://autodock.scripps.edu) and the calculation used to predict the list of binding
affinity scores is as follows:

ΔGBinding = ΔGvdW + ΔGelec + ΔGhbond + ΔGdesolv + ΔGtors
Where ΔGvdW accounts for the Van der Waals energy and calculates the “fitting” of
the molecule thereby defining the pocket or space where a ligand may dock to a
macromolecule. ΔGelec calculates the ionic or polar interactions between charged
atoms, ΔGhbond calculates hydrogen bonding between, for example, bases and carboxyl
groups, ΔGdesolv accounts for water molecules that surround the ligand and binding site
that need to be displaced for binding to occur, ΔGtors calculates the entropy or degrees
of freedom of the ligand and macromolecule. (Santos-Martins et al., 2014).

One major limitation of many docking simulations is setting the ligand and/or
macromolecule to be too rigid where rotatable bonds are set in a fixed position.
Although this may be considered a disadvantage it greatly reduces the computational
time needed to perform docking simulation. Rigidity of the macromolecule does not
allow for ligand-induced fit that is a critical factor when looking at enzyme ligand
interaction. This “rigidity” disadvantage can be overcome with Autodock whereby
side chains that are known to be important in binding interactions may be allowed to
be flexible.

This creates a more computationally intensive but more accurate

simulation with a better docking fit and score (Morris et al., 2009).

Previous studies have shown Autodock’s ability to screen binding interactions of small
ligands with PrAO. In one study a PrAO physiological substrate methylamine was
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successfully docked with PrAO. The lowest computational score showed methylamine
to be bound in the active site and the amine of methylamine to be hydrogen bonded to
TPQ and Asp336 as expected (Bonaiuto et al., 2010). A computational docking
simulation was employed to design a multi-target inhibitor to simultaneously inhibit
two enzymes, PrAO and acetyl-cholinesterase. AutoDock software was used to
compare a crystallised bound ligand / PrAO complex with the in-silico bound
equivalent to validate the method. Binding of a known ligand, galantamine, with the
co-factor TPQ in an X-ray structure was compared to a computationally docked
galantamine equivalent with PrAO. Thereinafter, known inhibitors from each target
were deconstructed into small fragments that were modelled into the in-silico model.
In all, this study produced four potential molecules that were designed in-silico for
experimental testing (Gharaghani et al., 2013).

These examples show Autodock to be effective in predicting probable binding
interactions between a ligand and macromolecule target, effectively scoring these
ligands in order of optimum interaction.

1.10 Proposed Research and Aims
The proposed research involves the exploration of the interaction between PrAO and
selected phytochemicals. Several compounds will be chosen as possible inhibitors of
PrAO. Compounds such as polyphenols and methylxathines are of particular interest.
These compounds are known to be associated with health benefits that offset the
negative effects associated with overly expressed PrAO. At the outset, we employed
a plate reader assay that monitored H2O2 produced from PrAO-catalyzed oxidation of
benzylamine. A direct spectrophotometric assay was employed to monitor the product
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benzaldehyde produced by benzylamine oxidation by PrAO at a wavelength of 254
nm. Enzyme kinetic studies were used to estimate IC50 and Ki for significant inhibitors.
Finally, computational docking software was used to predict binding interactions and
active site binding locations of some inhibitors of interest.

The aims of this research were to explore selected phytochemicals with known health
benefits for activity as PrAO inhibitors. The study focused on establishing the mode
of inhibition and identifying the structural features necessary to be a useful PrAO
inhibitor. We aimed to support our observations using computational modelling in an
attempt to identify inhibitor binding sites on the enzyme surface.

43

CHAPTER 2
2 Materials & Methods
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2.1

List of Reagents
Reagent

Supplier

Acetonitrile

Sigma

Acrylamide

Sigma

Adenine

Sigma

Adenosine

Sigma

4-Aminoantipyrine

Sigma

4-amino-phenol

Sigma

L-Alanine

Sigma

L-Arginine

Sigma

Ascorbic Acid

Sigma

Benzaldehyde

Sigma

Benzylamine

Sigma

Benzylhydrazine Dihydrochloride

Sigma

8-Bromocaffeine

Sigma

Caffeic Acid

Sigma

Caffeine

Sigma

Catechol

Sigma

2 Chloromethyl benzimidazole

Sigma

L-Cysteine

Sigma

Cystic Acid

Sigma

EGTA

Sigma

Epicatechin

Sigma

Epicatechin Gallate

Sigma

Epigallocatechin Gallate

Sigma

D-Ethionine

Sigma

GABA

Sigma

Green Tea

Twinings

Horseradish Peroxidase

Sigma

Hypoxanthine

Sigma

Isatin

Sigma

D-Iso-Leucine

Sigma

Methyl Gallate

Sigma

1-Methyl-L-histidine

Sigma

1-Methylimidazole

Sigma
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1,7-Dimethylxanthine

Sigma

7-Methylxanthine

Sigma

Monoamine Oxidase

In house

N-alpha-methylhistamine Dihydrochloride

Sigma

D-Norvaline

Sigma

Octopamine

Sigma

Lisofylline

Sigma

L-Ornithine

Sigma

Phenylalanine

Sigma

Phloroglucinol

Sigma

Potassium Phosphate Dibasic

Sigma

Pyridoxine

Sigma

Quercetin

Sigma

Riboflavin

Sigma

Rutin

Sigma

Saponin

Sigma

Semicarbazide

Sigma

Primary Amine Oxidase

Langanbach Services

D-Serine

Sigma

Spermidine

Sigma

Spermine

Sigma

Sucrose

Sigma

Sulphanilamide

Sigma

Theobromine

Sigma

Theophylline

Sigma

Trigonelline

Sigma

TRIS

VWR

Tryptamine

Sigma

Umbelliferone

Sigma

Uric Acid

Sigma

Vitamin B1

Sigma

Vitamin B12

Sigma

Vanillic Acid

Sigma

Xanthine

Sigma
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2.2

List of Instrumentation & Equipment

Instrument/Equipment

Manufacturer & Type

Balance Weigh Scales

Mettler – college 150

6-Cell Automated Cuvette Changer

Shimadzu CPS-240A

Centrifuge

Eppendorf – 5415 R

Filter Paper

WhatmanTM 0.45 μM Polyamide

Hand Held Homogeniser

Thomas

Heating Bath

Julabo - 5

Heating Block and Stirrer

IKA RH – KT/C

HPLC

Waters 2690

HPLC Acquisition Software

Empower 2

HPLC Detector

Waters 2487 Dual Absorbance

Visible Kinetics Software

Softmax Pro – 6.2.1

UV Kinetics Software

UV Probe – 2.42

UV-Vis Spectrophotometer

Shimadzu - UV-2600

pH Meter

Corning - 240

UV-Vis Spectrophotometer Plate Reader

Molecular Devices – Spectra Max M3

Vortex mixer

Wisemix – VM-10

Water Purification Unit

Millpore Milli-U10

Sample Vials

VWR Glass 2 mL

Separation Column

Nucleosil C18 (3.9 x 150 mm)

Spectrophotometer Plate Reader UV-Vis

Molecular Devices – Spectra Max M3

Vacuum Pump

WELCH - MPC090E

96 Well Plates

Greiner – Flat Bottom Crystal Clear Plate
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2.3

Preparation of PrAO for Storage and Use

Lyophilised bovine plasma PrAO was purchased from Langanbach Services.
PrAO was reconstituted to a final concentration of 10 mg.mL-1 from a pure
lyophilised state with 50 mM phosphate buffer (pH 7.2) which was gently inverted
to mix and aliquoted into 0.5 mL aliquots into 1.5 mL eppendorfs. The enzyme
solution was retained in long-term storage at -20ºC. From these aliquots working
stock concentrations of PrAO were made up to approximately 0.3 mg.mL-1 by
adding 30 µl to a final volume of 1000 µl of buffer. This was then brought to a
final working activity concentration of 1.2 U.µl-1 by adding 50 µl of working stock
solution to 200 µl of a final assay volume.

All working stock solutions were stored on ice during use. For short-term storage,
the working concentration of enzyme was refrigerated at 4ºC due to an observed
decrease in enzyme activity beyond three freeze thaw cycles. The enzyme was
placed on ice at all times while assays were being carried out.

2.4

Preparation of Substrates, Controls and Inhibitor Solutions

All solutions were prepared with deionised water from a Millipore Milli-U10
water purification system and compounds were weighed using a 4 decimal place
balance (Mettler – College 150 weigh scales). Volumes were measured either with
0.5 μL – 5000 μL pipettes (Gilson) or by use of appropriate volumetric glassware.
Where solutions were required at a certain pH, a Corning – 240 pH meter was used
to monitor pH during buffer preparation, with adjustments made using an
appropriate acid/base. The pH probe was calibrated when first used each day with
pH 4, 5 and 10 standard buffer solutions as per manufacturer’s recommendations.
Any poorly soluble compounds tested were either solubilized in DMSO or ethanol,
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as advised by the supplier’s chemical data sheet, at a minimal percentage to
solubilise to a maximum of 5% (v/v) concentration. A control using this
percentage of solvent solution was examined in the presence of the enzyme under
normal experimental conditions to identify any inhibitory effects on catalysis, if
any.

2.5

Standard U.V. Spectrophotometric assay of PrAO; Monitoring
Benzaldehyde Production at 254 nm

The oxidative deamination reaction of PrAO was recorded by monitoring
benzaldehyde aldehyde production from benzylamine at 254 nm. This was a
continuous spectrophotometric assay. The substrate used was benzylamine (final
concentration: 5.0 mM), which PrAO converts to benzaldehyde, ammonia and
H2O2. The reaction mixture contained 1.2U of PrAO, 50 mM potassium phosphate
buffer (pH 7.2) and benzylamine (5 mM). When required, a selected inhibitor or
semicarbazide (1 mM) were added to provide a control, to a total final volume of
1 mL in a Quartz cuvette. Reaction rates were monitored in a Shimadzu UV-2600
UV-Vis Spectrophotometer with a 6-cell cuvette automated changer, employing
the UV Probe–2.42 software. All components of the reaction mixture were
screened for absorbance interference in the 254 nm or 498 nm range via a spectral
scan between 200 nm – 500 nm or 350 nm – 700 nm depending on assay method
in question. Each compound tested was examined in the buffer being used for the
assay, before and after each assay, to verify that no unusual spectral readings that
might offset, or interfere with, the data were obtained. Quartz cuvettes were used
and cleaned after each use by soaking cuvettes in 50% (v/v) sulfuric acid 2.0M and
50% (v/v) de-ionised water to remove any residues that may occur over time.
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Positive controls for PrAO, without inhibitor, and negative controls using 1 mM
semicarbazide, a well-established inhibitor of PrAO (O'Sullivan et al., 2004) at
this concentration, were employed. All assays were performed in triplicate at 37ºC.

2.5.1 Holt Coupled-Assay of PrAO Monitoring Hydrogen Peroxide
Production at 498 nm.
In addition to the continuous spectrophotometric assay we also employed a
colourimetric assay (the method of Holt and Palcic (2006). This assay was easily
automated as a plate reader assay and was used for initial screening of possible
inhibitors. It monitors H2O2 production via a coupled reaction and formation of a
quinoneimine dye (see below section 2.5.2) and can therefore use a wider range of
substrates than the spectrophotometric assay (section 2.5). However, as detailed
below, we found certain substrates or inhibitors, could react with the redox dye
used in this assay to provide anomalous readings.
The activity of PrAO was determined by following the production of H2O2 at 498
nm, by the method of Holt and Palcic (2006). The enzyme was typically assayed
in the presence of 5.0 mM benzylamine and 1.2U PrAO. Triplicate assays were
carried out in a total reaction volume of 200 µL in 96-well microtitre plates, at
37ºC, using a SpectraMax 340PC plate reader (Molecular Devices, Inc. Sunnyvale,
CA 94089-1136, USA). Control assays for the coupling system, in the presence of
0.lM H2O2, 1mU/mL HRP but in the absence of PrAO were employed. Each
compound was assayed both in intra and inter triplicates, at a final concentration
of 1 mM at 37ºC, before adding substrate.
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GraphPad Prism (Version 5.0) was used for all curve fitting procedures. Doublereciprocal plots were created for illustrative purposes only. Mean standard errors
were determined from at least 3 separate experiments.

2.5.2 Preparation of Chromogenic Solution for H2O2 Detection and Initial
Rate Determination.
The chromogenic solution for the detection of H2O2 produced by oxidation of
amines by PrAO contained 1 mM vanillic acid, 0.5 mM 4-aminoantipyrine and
horseradish peroxidase (4U/mL) in a ‘physiological’ buffer (200 mM potassium
phosphate buffer, pH 7.6). The pH of the buffer was adjusted to 7.6 with 0.1M
NaOH. The solution was then stored at 4ºC in a universal tube and covered in
tinfoil, since the solution is light sensitive. The peroxidase produces a coupled
reaction via H2O2 production, resulting the formation of a quinoneimine dye,
which absorbs strongly at 498 nm.

2.5.3 HPLC Assay for Monitoring Inhibition of Benzaldehyde at 254 nm
Benzaldehyde formation from benzylamine by PrAO was monitored at 254 nm
using a Waters 2487 dual absorbance detector and a Waters 2690 separations
module. A Nucleosil C18 (3.9 x 150 mm) separation column was used with a flow
rate of 0.8 mL/min and at a working pressure of approx 800 psi. This HPLC assay
method was performed using isocratic elution with an optimum mobile phase
blend of Acetonitrile and deionised water (50:50), which was filtered and
degassed. Chromographic data was acquired and processed using an Empower TM
2, chromatography data software package.
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Benzaldehyde standards were first prepared as controls and peaks eluting were
monitored at 254 nm to measure retention times and peak areas. Standards were
prepared from pure Benzaldehyde (99.9%; Sigma) dissolved in a 50 mM
potassium phosphate buffer pH7.4. The standard curve was produced with seven
concentrations ranging from 10 μM – 120 μM to determine PrAO product (i.e.
benzaldehyde) concentrations.

Inhibition assays were carried out in triplicate in a 50 mM phosphate buffer (pH
7.2) containing 1.2 U of PrAO, 5 mM benzylamine and variable concentrations of
selected inhibitor in a final volume of 1 mL. All inhibition reactions and controls
were thoroughly mixed, allowed to incubate for 3hrs at room temperature (22 °C)
and then simultaneously quenched by heating at 85°C for ten minutes. The samples
were centrifuged at 20,800 g for 20 minutes. 10 μL of each sample was injected
with an acquisition time of 6 minutes for each sample. Positive and negative
controls were included as standard U.V. spectral analysis method (see Section 2.5).

2.6

Green Tea Extraction

A crude extract of green tea (Twinings) was prepared from dried tealeaves in
distilled water. In brief, this entailed boiling 2.5 g tealeaves in 100 mL of dH2O
(prepared by passage through a Millpore Milli-U10 purification unit) for 5
minutes. The extract was then sieved and initially filtered through standard grade
Whatman filter paper, then filtered using a 0.45 μM cartridge filter and stored at
4°C. The inhibition range was obtained by serial dilution with assay buffer until
an inhibiting rate was achieved (noted as 1:100 dilution of the original extract).
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2.7

IC50 Inhibition Plots

IC50 plots utilizing GraphPad Prism were carried out to ascertain 50% inhibition
concentrations for each compound showing significant inhibition (Version 5.0).
Assays were carried out with PrAO saturated with substrate (5 mM Benzylamine)
in the presence of the chromogenic coupled reaction solution and inhibitor as
previously (see Section 2.5.2). Rates were recorded in units of mAbs.min-1. Kinetic
assays were performed under steady state conditions, as defined by a linear
reaction progress curve. All kinetic parameters were calculated using the
Michaelis-Menten equation function within GraphPad Prism. All assays were
carried out in triplicate. IC50 sigmoidal curve plots were produced by plotting
initial rate against the logarithmic concentration of inhibitor using GraphPad
Prism.

2.8

Lineweaver Burk Plots and Ki Estimation

Lineweaver Burk plots at different inhibitor concentrations were employed to
identify the pattern of PrAO inhibition as determined by the observable effects on
Km and/or Vmax parameters. Ki values were estimated from resulting slope values
replots. In brief, this approach provided a simple screening mechanism to examine
compounds that demonstrated significant inhibition. Assays were carried out using
1 mM to 5 mM substrate concentrations for each inhibitor concentration. As per
Section 2.8, kinetics analyses were performed employing the Michaelis-Menten
equation to estimate kinetic parameters. All assays were carried out in triplicate.
Plots were then graphed using GraphPad Prism (Version 5.0) and employed the
embedded Lineweaver Burk equation function which subsequent non-linear
regression analysis. The slopes from the individual reciprocal plots, were used to
determine corresponding Ki values.
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2.9

PrAO Computational Docking Studies

AutoDock tools 4.0 (ADT; http://autodock.scripps.edu) was the computational
docking software used to examine binding interactions between PrAO and various
ligands. The software and hardware resources of the DJEI/DES/SFI/HEA Irish
Centre for High-End Computing (ICHEC) were utilized. Ligand files were sourced
in the ChEMBL section of the European Bioinformatics Institute (EMBL-EBI)
website (https://www.ebi.ac.uk/chembl/) and saved in a mol2 format. Ligand
tautomers and stereoisomers were enumerated using Biovia Discovery Studio
(Version 4.0). Ligand files were then converted to a Protein Data Bank, Partial
Charge (Q), & Atom Type (T) format (PDBQT) using ADT and rotatable bonds
were identified and set for flexible ligand docking.

The enzyme structure of bovine PrAO was taken from the protein data bank (PDB;
http://www.rcsb.org/pdb/home/home.do) under the PDB ID 2PNC (Holt et al.
2008). Structurally relevant hydrogen atoms were added to heavy atoms such as
carbon, oxygen and nitrogen to fulfill valency requirements. The structure was
checked for any additional water molecules that could be added from the original
x-ray-crystallography structure and saved. A separate, flexible, file was created
that permitted certain side chains of the macromolecule to be flexible. Flexible
residue side chains were chosen based on prior research as noted in the literature
and were: Arg173, Asp177, Ile232, TPQ470, Asn469, Leu468, Thr466, Thr381
and Met384. These amino acids and or location were noted in the literature to be
involved in inhibitor interactions (Jakobsson et al., 2005; Bligt-Lindén et al., 2013;
Gharaghani et al., 2013).
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2.9.1 Grid File Generation
The parameter file for each atom type found on the structure of bovine PrAO was
created from the known energy values for each atom hosted within the internal
AutoDock valuation file. A grid file was generated from this validation file.
AutoDock’s parameter atom file may not have all atom parameters available and
some were added manually (http://autodock.scripps.edu/faqs-help/how-to/addingnew-atom-parameters-to-autodock). In this study, the value for a copper atom was
not

found

in

this

file

and

was

manually

inserted

(http://bioinf.modares.ac.ir/Courses/Docking/AD4 parameters.dat).

2.9.2 Grid Size Determination
A rectangular grid size of 38Å × 40Å × 70Å with a spacing of 0.375Å was selected
as the default grid size. A grid center location of 41.807 × -10.752 × 27.939 was
placed on the bovine PrAO structure covering the active site entrance, the active
site and active site funnel. The grid point and the interaction energies between the
probe and the target point are computed from the parameter atom file. Grid points
spacing typically ranged from 0.2Åto 1.0Å, where the default was 0.375Å. This
completed the entire grid value of energies for each atom type selected in the grid
box and was subsequently used as a reference during the docking simulation,
thereby speeding up the calculation process (Morris et al., 2009).
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2.9.3 Docking Algorithm
The docking algorithm chosen was a Genetic Algorithm (GA) with 50 GA runs
with a maximum number of evaluations of 2,500,000 and a set value of the number
of GA generations of 27,000. All other algorithm variables were set to the default
parameters.

Docking results were analysed using the ADT software. The resulting output file
provided a ranked list in order of the top hit (this being the lowest binding energy)
of each pose, along with a lowest mean bind. Resulting images, or poses, were
generated with Biovia Discovery Studio (Version 4), in combination with Python
Molecular Viewer (PMV) (http://mgltools.scripps.edu/documentation/tutorial/
python-molecular-viewer). In this research the poses are represented in stick
model or atomic fill display, visually indicating the predicted hydrogen bonding,
electrostatic charges, pi-pi interactions and Van der Waals forces of the docked
ligand interaction with side chains of the enzyme.
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CHAPTER 3
3

Results
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3.1

Introduction

A wide range of molecules found in foods and beverages have been associated
with health benefits (Chapter 1, Section 1.0). In this Chapter the effect of a range
of polyphenols, methylxanthines, selected amino acids and vitamins on PrAO
activity are investigated. The aim was to examine whether these compounds might
influence PrAO activity and provide a link between the health benefits ascribed to
specific food components and a known therapeutic target. This approach was
prompted by previous studies in these laboratories establishing that caffeine was
an inhibitor of PrAO (Olivieri and Tipton, 2011) and the suggestion that caffeine
might be used therapeutically to treat a range of conditions (Che et al., 2012).
Despite the interest in caffeine as a potential PrAO inhibitor, little is known about
the effect of related methylxanthines on its activity, or indeed, the effects of a
broader class of phytochemicals on the enzyme. In the course of this study a range
of phytochemicals were examined as well as some structurally related xenobiotics.

The research herein is separated into sections that focus on green tea catechins,
methylxanthines, selected amino acids and vitamins as well as specific
endogenous and xenobiotic compounds. Data are primarily represented in bar
graph form with associated tables indicating statistical significance throughout the
chapter. Furthermore, a synoptic table of results can be found at the end of the
chapter (see Tables 3.3 and 3.4). Where compounds were of particular interest,
IC50 and Ki estimations were performed. Where compounds showed significant
inhibition, molecular modeling software was utilized in an attempt to identify their
binding sites on PrAO.
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Colorimetric and UV-Vis spectrophotometric assays were initially employed to
study the effect of polyphenols on PrAO activity. However, the assay results were
anomalous with some polyphenols inhibiting PrAO at low concentrations whilst
giving increased activity at higher concentrations. This necessitated the
development of an alternative HPLC assay that was not subject to interference and
provided a direct readout of product formation. Our initial screening studies relied
on a colorimetric assay or the spectrophotometric assay described in Chapter 2
while the HPLC assay was adopted for all later studies involving polyphenols.

3.2

HPLC-based PrAO assay monitoring benzaldehyde formation

A simple HPLC based assay to monitor Benzaldehyde formation from
Benzylamine was devised. Figure 3.1 shows a pure benzaldehyde standard
chromatogram using the HPLC method.

Fig. 3.1. HPLC chromatogram of a 40 μM pure benzaldehyde standard. The HPLC eluate was
monitored at 254 nm as described in Section 2.5.3. A retention time for Benzaldehyde of
approximately 3.0 minutes was observed. AU represents Absorbance Units.
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Benzaldehyde formation from the substrate benzylamine (Fig.3.2), produces a
similar chromatogram showing a peak with a comparable retention time (approx.
3 minutes) thereby verifying the HPLC method’s ability to monitor benzaldehyde
formation. This assay was kept as standard for inhibition studies as described in
section 2.5.3 for all further studies.

Fig. 3.2. HPLC chromatogram of benzaldehyde produced from PrAO-catalyzed oxidation of
Benzylamine. Benzylamine was converted to the product Benzaldehyde as described in section
2.5.3 (i.e. 1.2 units of enzyme, 5 mM benzylamine in 1 mL of phosphate buffer pH.7.2). The assay
duration was 3.0 hrs. Enzyme activity was quenched by heating to 85 ºC and protein removed by
centrifugation before HPLC injection.

A chromatogram showing the effect of PrAO inhibition by the potent and specific
inhibitor semicarbazide is shown in Fig. 3.3. Semicarbazide addition caused the
disappearance of the benzaldehyde peak as expected. This clearly showed that the
benzaldehyde formed was as a result of enzyme activity.

This experiment

established that the HPLC method could be used to measure PrAO activity.
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Fig. 3.3. HPLC chromatogram showing PrAO inhibition using 1 mM semicarbazide. The assay
was performed by monitoring benzaldehyde production at 254 nm as described in section 2.5.3.
Assay time was 3hrs. Enzyme activity was quenched by heating to 85 ºC and protein removed by
centrifugation before HPLC injection.

An HPLC assay standard curve using pure benzaldehyde standards was linear over
the working range (Fig. 3.4), indicating that the HPLC method is appropriate for
detecting benzaldehyde over the range of concentrations used in this study.
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Fig. 3.4. HPLC assay standard curve pure benzaldehyde (99.9%). Standard concentrations of
Benzaldehyde were injected ranging from 10 μM to 120 μM. The measuring of peak area at 254
nm was as described in section 2.5.3. linear regression R² = 0.9976.

Fig 3.5 shows a 3.0hr PrAO assay progress curve monitoring benzaldehyde
production monitored at 254 nm using the UV spectrophotometric assay. The
production of Benzaldehyde product over the three-hour incubation time was
linear. Assay conditions for this plot are the same as for the standard assays used
in all HPLC screening of PrAO as described in the methods section 2.5.3.
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Fig. 3.5. Progress curve of PrAO benzaldehyde formation over a 3hr period. Absorbance readings
were monitored continuously at 254 nm. Assays were carried out using the standard conditions as
described in section 2.5.3. The horizontal axis units are in seconds.

The HPLC assay was clearly a convenient method to monitor PrAO activity and
was not subject to the interference we had observed in our initial studies with the
colorimetric assay. This assay was used to examine the effect of a range of
bioactive compounds on PrAO activity.
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3.3

Polyphenol Screening of PrAO Modulation

3.3.1 Green Tea Catechins
Green Tea catechins have long been associated with a wide variety of health
benefits (see Chapter 1 Section 1.8.2). It was of interest to examine the interaction
of these compounds with PrAO. In this section, Green Tea extracts along with pure
green tea catechins; epigallocatechin gallate, epicatechin gallate and epicatechin
(Fig 3.6) were examined for inhibition of PrAO.

As indicated above (section 3.2), the colorimetric assay used for PrAO inhibition
studies was found to give problems in our hands. That prompted us to devise an
HPLC based assay method to monitor PrAO activity. In the following section we
describe the issues that arose with the colourimetric assay and how reliance on this
assay can give rise to misleading conclusions.

3.3.1.1

Crude Green Tea extracts

Initial screening of green tea extracts used a colorimetric microtiter plate reader
assay (see Chapter 2, section 2.5.1) since it was convenient and allowed for
screening of a large number of compounds simultaneously.
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Fig. 3.6. Structures of selected catechins screened for PrAO inhibition.
http://www.chemspider.com/Chemical-Structure

The first experiments examining at the effect of Green Tea on PrAO activity were
performed with a crude extract that was prepared as described in Section 2.6. Fig.
3.7 shows a 1:100 dilution of crude green tea extract tested for inhibition of PrAO
at various concentrations. These results show an apparent inhibition at low
concentrations and, surprisingly, an apparent increase in PrAO activity at higher
concentrations. These findings pointed to inhibition by Green Tea components
followed by subsequent activation. GABA a primary amine present in Green Tea
was first tested as it was a likely compound to be a substrate or inhibitor of PrAO,
but no modulation was found upon testing (see Table 3.3). Since it was not possible
to envisage a mechanism whereby an inhibitor would become an activator at
higher concentrations we were prompted to this explore this phenomenon further
using pure components of Green Tea. It is well known that the major bioactive
properties of Green Tea are ascribed to the catechins. The dominant catechins
found in Green Tea are epigallocatechin gallate (EGCG), epicatechin (EC) and
epicatechin gallate (ECG).
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Fig. 3.7. 1:100 dilution of crude green tea extract was examined in an inhibition assay ranging
from 1µl to 250µl of extract added to a final volume of 1000µl. The data show inhibition by the
Green Tea extract at low concentrations and an apparent rise in PrAO activity as concentration of
green tea extract increases. Assays were performed using the colorimetric plate reader assay at
250nM, as described in chapter 2, Section 2.5, monitoring dye reduction. All assays were
performed in triplicate. Positive and negative controls were employed. Data were analyzed using
ANOVA, Significant differences are denoted by an asterisk (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001)
using ANOVA and Dunnett’s test.

3.3.1.2 Catechins as PrAO inhibitors
It was possible that inhibition studies using a crude Green Tea extract might be
complicated due to the large number of compounds in the crude extract.
Accordingly, we decided to examine components of Green Tea individually.
Firstly, epicatechin testing of PrAO showed no significant inhibition across the
range of concentrations tested (Fig. 3.8).
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Fig. 3.8. Epicatechin inhibition of PrAO with concentrations of epicatechin from 0.65μM to
680μM. The data show no significant decrease in rate (% activity) as concentration increases
compared to control. Assays were performed at 250nM using the spectrophotometric U.V assay
monitoring aldehyde production in intra and inter triplicates as described in section 2.5. Positive
controls with PrAO and substrate and negative inhibition controls with PrAO, substrate and 1 mM
semicarbazide were included.

Surprisingly, micromolar concentrations of EGCG, when tested as an inhibitor of
PrAO, showed inhibition at lower concentrations and a rise in activity as
concentration increased (Fig. 3.9). Since this was broadly the same pattern of
inhibition/activation observed with a crude extract we concluded that EGCG was
responsible for this puzzling behavior.
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Fig. 3.9. Epigallocatechin gallate inhibition of PrAO at concentrations ranging from 500nM to
500μM. Data show an initial decrease in activity at low concentrations followed by an increase in
rate (% activity) as concentrations increase when compared to the control. Assays were performed
at 250nM using the colorimetric plate reader assay as described previously, see chapter 2 section
2.5, monitoring aldehyde production in triplicate. Positive controls with PrAO and substrate and
negative inhibition controls with PrAO, substrate and 1 mM semicarbazide were included. An
asterisk denotes a significant difference between treatments and the control (**P ≤ 0.05; ***P ≤
0.001) using ANOVA and Dunnett’s test.

It was even more surprising when the same pattern of inhibition followed by
activation was found with epicatechin gallate (Fig 3.10), i.e. inhibition at low
concentrations with an increase in rates at a higher concentration of the inhibitor;
although the increase in rates at high concentrations was much less than observed
with epigallocatechin gallate
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Fig. 3.10. ECG Inhibition of PrAO. with concentrations from 1μM to 100μM. Assays were
performed at 250nM using the colorimetric plate reader assay monitoring aldehyde production in
intra and inter triplicates as described in chapter 2 section 2.5. Positive controls with PrAO and
substrate and negative inhibition controls with PrAO, substrate and 1 mM semicarbazide were
included. An asterisk denotes a significant difference between treatments and the control (***P ≤
0.001) using ANOVA and Dunnett’s test.

Since there was a possibility that the colourimetric assay might be interfering with
the findings we decided to make use of the HPLC based assay method that could
directly monitor benzaldehyde formation. This assay was free of the redox dye
which might react with catechins and cause anomalous findings. The HPLC assay
revealed a startling reaction: we observed the formation of benzaldehyde in the
absence of enzyme. In fact, when the non-enzymatic formation of benzaldehyde
(deamination) was subtracted from the rate due to enzyme catalysis it was seen
that continuous inhibition of PrAO was occurring as EGCG and ECG
concentrations were increased (Fig 3.11 and 3.12).
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Fig. 3.11. EGCG inhibition of PrAO subtracting the non-enzymatic deamination reaction of
EGCG with benzylamine (autodeamination). PrAO activity was measured by HPLC at 254nM for
benzaldehyde detection. Assays used the HPLC assay described in Chapter 2, section 2.5.3.
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Fig. 3.12. Epicatechin gallate inhibition of PrAO subtracting absorbance values due to the nonenzymatic deamination reaction between epicatechin gallate and benzylamine. PrAO activity was
monitored by HPLC at 254nM for benzaldehyde detection. Assays were performed as single data
points using the HPLC assay described in materials and methods section 2.5.3. These findings
show that micromolar levels of catechin can inhibit PrAO but that such inhibition may be masked
by a non-enzymic reaction between Benzylamine and catechins.
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Upon further investigation of the literature it was discovered that a research team
(Akagawa et al., 2005) had previously documented this reaction and provided a
proposed mechanism (Fig 3.13). Thus, a non-enzymatic reaction between
polyphenols and certain amines can give rise to deamination that mimics Amine
Oxidase activity.

Fig. 3.13. Schematic showing the proposed deamination reaction between a polyphenol and a
primary amine forming the products H2O2, benzaldehyde and ammonia. This is similar to the PrAO
oxidation reaction mechanism with a primary amine forming the same end products (Akagawa et
al., 2005).

3.3.1.3 Caffeic Acid as an inhibitor of PrAO
Caffeic acid is a minor polyphenol component of coffee. It is known to react nonenzymatically with polyphenols as previously reported by Akagawa and coworkers (2005; Fig. 3.13). Caffeic acid (Fig. 3.14) was screened as an inhibitor of
PrAO using the HPLC method. The previously reported non enzymic reaction with
benzylamine was observed. Unlike the reaction with catechins no residual PrAO
inhibition was observed (Fig 3.15).

71

Fig. 3.14. Structure of caffeic acid. http://www.chemspider.com/Chemical-Structure
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Fig. 3.15. Caffeic acid inhibition of PrAO. By subtracting the observed non-enzymatic
deamination reaction between caffeic acid and benzylamine. PrAO activity was measured by
HPLC at 254nM for benzaldehyde detection. Assays were carried as single data points out using
the HPLC assay described in materials and methods section 2.5.3.
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3.3.1.4 Catechin stability test
There was a possibility that under the conditions of the assay being used in these
studies that catechins might be unstable leading to the formation of new species.
EGCG was examined for stability over a 4hr period- the time taken to carry out
the inhibition assays with PrAO (Fig. 3.16).

Fig. 3.16. A 4hr time dependent scan of a 100μM concentration of EGCG to monitor the stability
of EGCG over time. EGCG control, EGCG with hydrogen peroxide and EGCG heated to 37°C
were scanned. Lambda max for EGCG is approx. 279nM and spectral scans were taken spanning
this wavelength.

These data clearly show that the non-enzymic formation of benzaldehyde is
causing apparent activation at high concentrations of ECG or ECGC. Such a
reaction is expected to increase as the concentration of catechin rises. The
subtraction of this rate from the overall rate of benzaldehyde formation shows that
a residual inhibition of PrAO observed. This finding shows that the observed
effect of EC and ECGC on PrAO has two components: a non-enzymic rate that is
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more pronounced at high catechin concentrations and an apparent direct effect on
PrAO catalysed benzaldehyde formation. The experiment with caffeic acid
showed that this type of interaction was not found for all polyphenols and appears
to be unique to catechins containing the gallate moiety.

3.3.2 Computational Modelling of the binding of ECG, EGCG, and
Epicatechin to PrAO
Computational modelling of ECG, EGCG and EC was carried out to examine
binding interactions with PrAO. A computational model for Bovine PrAO was
constructed as described in Section 2.9. The top ranking scores (the more negative
the ranking value the more energetically favorable the binding) and binding
interactions between inhibitor and PrAO residue side chains are detailed. Figure
3.17 shows a molecular surface representation of epicatechin gallate binding to
PrAO.

Fig. 3.17. Modelling Epicatechin gallate binding to PrAO. This interaction had a top rank docking
score of -5.76 (Gbind) as calculated by AutoDock Tools 1.5.6 when bound to PrAO. A molecular
surface representation with polarity shading is depicted for the docking interaction of ECG and
PrAO, indicating the active site entrance of PrAO and binding location of epicatechin gallate.
Residues labeled are Asn469, Asn231 and Arg173, which are at or near the active site entrance.
Polarity regions are indicated by grey hydrophobic, blue positively charged and red negatively
charged.
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Figure 3.18 depicts a computational stick model of the same binding depicted in
Figure 3.17 giving a more detailed image of the bindings and residues involved.

Fig. 3.18. A computational stick model representation of Figure 3.17. Image A shows epicatechin
gallate, shown in grey, to be externally bound to the enzyme in close proximity to the active site
entrance. Image B is a magnification of the binding interaction of image A, depicting polarity
regions such as blue for positively charged and red for negatively charged binding interactions.
The grey shading indicates hydrophobic regions. Image C shows the removal of the surface
representation, which depicts the hydrogen binding interactions via the gallated phenol group
binding to the amine group of Asn231 and also binding via other phenol groups to the amine group
of Asn469 and the hydroxyl group of Thr466, while giving a better visual of the ligand and
interacting side chains involved.

It is clear that binding of ECG at the active site covers a wide area and could block
substrate entry. Figure 3.19 and Figure 3.20 show similar molecular docking for
epigallocatechin gallate.
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Fig. 3.19. Epigallocatechin gallate had a top rank docking score of -6.91 (Gbind) as calculated by
AutoDock Tools 1.5.6 when bound to PrAO. A molecular surface representation with polarity
shading is depicted for the docking interaction of ligand and macromolecule, indicating the active
site entrance of PrAO and binding location of epigallocatechin gallate. Asn469 and Thr233 are
highlighted at or near the active site entrance. Polarity regions are indicated by blue, positively
charged and red, negatively charged, indicating potential charged binding interactions. The grey
shading depicts hydrophobic interactions.

Fig. 3.20. A computational stick model of Figure 3.19. Image A shows epigallocatehin gallate,
shown in grey, to be externally bound to the enzyme in close proximity to the active site entrance.
Image B is a magnification of the binding interaction of image A, depicting polarity regions such
as blue for positively charged and red for negatively charged, indicating potential charged binding
interactions. The grey shading indicates hydrophobic regions. Image C is the removal of the
surface representation, which depicts hydrogen bonding via the phenol groups of the gallate
binding to hydroxyl groups of both Thr466 and Tyr238, while giving a better visual of the ligand
and interacting side chains involved.
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Epicatechin gallate and epigallocatehin gallate were computationally modelled as
they significantly inhibited PrAO. Modelling of Epicatechin (EC), Figures 3.21
and 3.22, which did not significantly inhibit PrAO was performed to compare with
the other catechins.

Fig. 3.21. Epicatechin had a top rank docking score of -5.30 (Gbind) as calculated by AutoDock Tools
1.5.6 when bound to PrAO. A molecular surface representation with polarity shading is depicted for
the docking interaction of ligand and macromolecule, indicating the active site entrance of PrAO and
binding location of epicatechin. Asn469, Pro237 and Arg173are highlighted at or near the active site
entrance. Polarity regions are indicated by grey hydrophobic, blue positively charged and red
negatively charged, indicating potential binding interactions.
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Fig. 3.22. A computational stick model of Figure 3.21. Image A shows epicatechin, shown in grey, to
be externally bound to the enzyme in close proximity to the active site entrance. Image B is a
magnification of the binding interaction of image A, depicting polarity regions such as blue for
positively charged and red for negatively charged, ionic charged interactions between Asn469 Thr466
and Tyr238 with hydroxyl groups of epicatechin. The grey shading indicates hydrophobic regions.
Image C is the removal of the surface representation, which depicts the ligand and interacting side
chains involved more clearly

An overview of observations and findings of PrAO modulation with crude green
tea extract and a number of green tea catechins and related compounds is shown
in Figure 3.23.

Fig. 3.23 Overview of methods employed, and main findings observed with testing crude green
tea extract and green tea catechins as PrAO inhibitors.
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A summary table is shown below detailing inhibition and binding interactions
between catechins and PrAO (Table 3.1).

Table 3.1. Summary of binding interactions for selected catechins with PrAO as
predicted by AutoDock.
Docked
Compound
Epicatechin

Experimental Docking Hydrogen Hydrophobic
Ionic
PrAO
Score
Bonding
Interactions Interactions
Inhibition
(Gbind)
Yes
-5.76
Asn231,
Leu468
------------Asn469

gallate

Pro237

Thr466
Epigallocatechin

Yes

-6.91

Thr466

Pro237

--------------

Pro237

Thr466

Tyr238

gallate
Epicatechin

No

-5.30

---------

Tyr238

3.3.3 Octopamine Inhibition of PrAO
Octopamine is a primary amine that is ubiquitously found in nature (Fig. 3.24).
Figure 3.25 shows octopamine at two concentrations, compared against a control
for activity as a PrAO inhibitor.

Fig. 3.24. Structure of octopamine. http://www.chemspider.com/Chemical-Structure
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Fig. 3.25. Inhibition of PrAO by 1mM and 0.5mM concentrations of Octopamine. Assays were
performed by HPLC at 250nM monitoring aldehyde production and in triplicate. Positive controls
with PrAO and substrate and negative inhibition controls with PrAO, substrate and 1 mM
semicarbazide were included. An asterisk indicates a significant difference using ANOVA was
(**P ≤ 0.01; ***P ≤ 0.001).
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Since Octopamine showed significant inhibition of PrAO its kinetics were
explored further. Figure 3.26 is an IC50 plot for inhibition of PrAO by Octopamine.

Fig. 3.26. Octopamine IC50 plot of log concentration of inhibitor Vs % activity. , A IC50 of 3.26mM
± 0.8mM was estimated. Inhibitor concentrations ranged from 0.1mM to 100mM. Data shown are
the mean values ± SEM. Assays were performed in triplicate using the plate reader based
colourimetric assay at 37°C and pH 7.2. Data were fitted by non-linear regression analysis with
the aid of computer software GraphPad Prism, 5.0.
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Figure 3.27 shows the effect of Octopamine on the Km for benzylamine. The
resulting plot shows a mixed pattern of inhibition.

Fig. 3.27. Substrate (benzylamine) pattern of inhibition of PrAO by octopamine. A mixed type
pattern of inhibition is observed. All samples contained increasing concentrations of octopamine
(from 0.1mM to 10mM) and benzylamine from 1 to 5 mM. Data shown are the mean values ±
SEM, error bars not evident were less than the representation of the points. The initial rates (v =
abs 498 nm × 10−3 min) of hydrogen peroxide formation were determined at 37◦C and pH 7.2.
Data were fitted to the Michaelis–Menten equation with the aid of GraphPad Prism, 5.0 software.
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3.3.4 Quercetin
Quercetin is the most abundant plant polyphenol in the human diet - it belongs to
the flavanoid group. This molecule has many reported beneficial health properties
that are associated with many of the diseases associated with raised PrAO activity
as discussed in Chapter 1, Section 1.8. Figure 3.28 is the chemical structure of
quercetin. Figure 3.29 depicts quercetin being screened at two concentrations. Fig.
3.30 depicts an IC50 graph of Quercetin inhibition of PrAO while Figure 3.31
depicts a Lineweaver Burk plot.

Fig. 3.28. Chemical structure of quercetin. http://www.chemspider.com/Chemical-Structure

83

A c t iv it y ( % m e a n  S E )

100

80

***

60

***

40

20

0

C

t
on

ro

l

h
In

ib

i
it

on

C

t
on

ro

l
Q
10

0

u

c
er

et

in
Q

M
40



u

c
er

et

in

M

Fig. 3.29. Quercetin inhibition assay of PrAO with control, inhibition control and experimental
assay with 100μM and 40μM concentrations. Assays were performed at 498nM monitoring H 2O2
production in triplicate. Positive controls with PrAO and substrate and negative inhibition controls
with PrAO, substrate and 1 mM semicarbazide were included. An asterisk denotes a significant
difference between treatments and the control (***P ≤ 0.001) using ANOVA and Dunnett’s test.
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R2 0.898

Fig. 3.30. Quercetin IC50 inhibition plot showing log concentration of inhibitor Vs % activity,
giving an IC50 of 52.20μM ± 33.75μM. Inhibitor concentration ranged from 10μM to 500μM and
substrate concentration of 5mM benzylamine. Data shown are the mean values ± SEM, error bars
not evident were less than the representation of the points. Assays were performed in triplicate and
IC50 readings gained at 498nM at 37°C and pH 7.2. Data were fitted with non-linear regression
analysis with the aid of computer soft- ware GraphPad Prism, 5.0.
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Fig. 3.31. Substrate (benzylamine) patterns of inhibition of PrAO by quercetin. An uncompetitive
pattern of inhibition is observed. All samples contained increasing concentrations of quercetin
(from 0.02μM to 0.250μM) and benzylamine 1 to 5mM. Data shown are the mean values ± SEM,
error bars not evident were less than the representation of the points. The initial rates (v = abs498
nm × 10−3 min) of hydrogen peroxide formation were determined at 37◦C and pH 7.2. Data were
fitted to the Michaelis–Menten equation with the aid of computer soft- ware GraphPad Prism 5.0.
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3.3.5 Umbelliferone
Umbelliferone is a natural product of the coumarin family. Like quercetin, it is a
phenolic metabolite found ubiquitously in plants. Figure 3.32 depicts the structure
of umbelliferone. In Fig. 3.33, umbelliferone was screened for inhibition at two
concentrations. There was a significant difference between both treatments and the
control using ANOVA (P ≤ 0.001).

Umbelliferone

Fig. 3.32. Chemical structure of umbelliferone. http://www.chemspider.com/Chemical-Structure
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Fig. 3.33. Umbelliferone inhibition assay of PrAO with blank, control, inhibition control with
semicarbazide and experimental assay with 1mM and 100μM concentrations. Assays were
performed at 250nM monitoring aldehyde production and in triplicate. Positive controls with
PrAO and substrate and negative inhibition controls with PrAO, substrate and 1 mM semicarbazide
were included . An asterisk denotes a significant difference between treatments and the control
(**P ≤ 0.01; ***P ≤ 0.001) using ANOVA and Dunnett’s test.
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3.4

Methylxanthines and related compounds as PrAO inhibitors

Previous work in our laboratory had shown caffeine, a methylxanthine was an
inhibitor of PrAO. We decided to extend this work to examine related
methylxanthine structures found in the diet as PrAO inhibitors. The structures of
the methylxanthines screened in this study are shown in Figure 3.34. The effect of
caffeine, paraxanthine, theophylline, theobromine and 7-methylxanthine on PrAO
at fixed concentrations of 500 µM and 1.0 mM were examined using the HPLC
assay as outlined above (Section 3.2).

Fig. 3.34. Structures of the caffeine related methylxanthines considered in this study. These
naturally occurring compounds are all N-methylated derivatives of xanthine.
http://www.chemspider.com/Chemical-Structure.

Of the five methylxanthines screened only caffeine and theobromine showed
substantial inhibition of PrAO. This was a highly significant finding and showed
that a specific pattern of methylation was required for inhibition. Surprisingly, the
other compounds tested, theophylline, paraxanthine and 7-methylxanthine, had
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relatively little effect (Fig. 3.35) despite their structural similarity to caffeine and
theobromine.
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Fig. 3.35. Effect of selected methylxanthines at 500µM and 1 mM concentrations on PrAO
activity. Activity was measured at 254 nm for benzaldehyde detection. Assays were performed
using the HPLC assay described in materials and methods section 2.5.3. Positive controls with
PrAO and substrate and negative inhibition controls with PrAO, substrate and 1 mM semicarbazide
were included. All assays were carried out in triplicate. An asterisk denotes a significant difference
between treatments and the control (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001) using ANOVA and
Dunnett’s test.

Since caffeine is a derivative of xanthine, several related compounds were tested
as PrAO inhibitors. Figure 3.36 shows that neither xanthine nor a range of similar
compounds had a significant inhibitory effect on PrAO activity at the
concentrations used herein. The structures of these compounds are shown in Fig
3.37.
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Fig. 3.36. Effect of selected xanthines and related compounds at 500µM and 1 mM concentrations on PrAO
activity. Benzaldehyde formation was measured at 254 nm using the HPLC method. Assays were performed as
described in materials and methods Section 2.5.3 Positive controls with PrAO and substrate and negative
inhibition controls with PrAO, substrate and 1 mM semicarbazide were included and results carried out in
triplicate.

Fig. 3.37. Structures of selected compounds structurally related to caffeine: adenine, adenosine, 8bromocaffeine, nicotinamide, uric acid and xanthine screened for PrAO inhibition.
http://www.chemspider.com/Chemical-Structure
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Caffeine contains an imidazole ring attached to a pyrimidinedione ring structure.
Therefore, a range of diazoles were tested for PrAO inhibition (Fig. 3.38).
Imidazole was the only compound of this group to show significant albeit modest
inhibition (P ≤ 0.05), but at a higher concentration than caffeine or theobromine,
so further testing was not pursued. Structures of the diazoles are given in Fig. 3.38.
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Fig. 3.38. Effect of selected diazoles screened at 500µM and 1 mM for inhibition of PrAO. Assays
were performed using the HPLC assay described in materials and methods Section 2.5.3. Positive
controls with PrAO and substrate and negative inhibition controls with PrAO, substrate and 1 mM
semicarbazide were included and results carried out in triplicate. An asterisk denotes a significant
difference between a treatment and the control (*P ≤ 0.05) using ANOVA and Dunnett’s Test.

Fig. 3.39. Structures of Imidazole, 1-Methyl-Histidine and Methylimidazole diazole compounds
selected for PrAO inhibition. http://www.chemspider.com/Chemical-Structure
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As shown in Figures 3.35, 3.36 and 3.38, theobromine is the most potent inhibitor
of PrAO of all the caffeine-related compounds tested. An IC50 plot (Fig 3.40)
showed that theobromine had an IC50 of 427.9 μM ±108 µM for the oxidation of
benzylamine by PrAO.

R2 0.9772

Fig. 3.40. Theobromine IC50 inhibition plot showing log concentration of inhibitor vs % activity.
From this data an IC50 of 427.9 μM ±108 µM was estimated. Inhibitor concentrations ranged from
0.1 mM to 5 mM using concentration 5 mM benzylamine as substrate. Data shown are the mean
values ± SEM, error bars not evident were less than the representation of the points. Assays were
performed in triplicate and IC50 readings obtained at 498 nm at 37°C and pH 7.2 using the
colorimetric assay described in Chapter 2. Data were fitted with non-linear regression analysis
with the aid of GraphPad Prism, 5.0 software.

The nature of PrAO inhibition by Theobromine was further explored by examining
its effect on kinetic parameters for benzylamine oxidation. (Fig. 3.41).
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Fig. 3.41. Pattern of inhibition of PrAO catalysed benzylamine oxidation by theobromine. A Noncompetitive pattern of inhibition is observed. Concentrations of theobromine were varied from 100
to 600 μM and benzylamine from 1 to 5 mM. Data shown are the mean values ± SEM, where error
bars are not evident they were less than the representation of the points. The initial rates (v =
abs498 nm × 10−3 min) of hydrogen peroxide formation were determined at 37◦C and pH 7.2. Data
were fitted to the Michaelis–Menten equation with the aid of computer software GraphPad Prism,
5.0. The values of 1/Vmax app were plotted against the concentration of inhibitor to obtain a Ki
estimate (−Ki = intercept on the X axis of the plot on the right) of approximately 275.6 μM (+/- 63
μM) as shown in the inset graph.
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3.4.1 Testing of Lisofylline as an inhibitor of PrAO
Lisofylline, a therapeutic used for the treatment of diabetes and inflammation, two
diseases associated with raised PrAO activity, was examined due to its close
similarity in structure to methylxanthines. The mechanism of action for this drug
is not clearly understood and testing was performed (Fig. 3.42) to probe PrAO
inhibition. There was a statistical significance between treatments and the control
(P ≤ 0.001), although the effect was not dramatic. The structure of lisofylline is
shown in Fig. 3.43.
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Fig. 3.42. Lisofylline inhibition of PrAO at 1 mM and 0.5 mM concentrations. Assays were carried
out at a wavelength of 498 nm using the Holt method as described in the methods section 2.5.1
monitoring H2O2 production. Positive controls with PrAO and substrate and negative inhibition
controls with PrAO, substrate and 1 mM semicarbazide were included. All assays were carried out
in triplicate. Data shows a small but significant difference (*P ≤ 0.05; ** P ≤ 0.01) value according
to ANOVA and Dunnett’s test.
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Fig. 3.43. Structure of lisofylline. This compound was screened for PrAO inhibition.
http://www.chemspider.com/Chemical-Structure

The degree of inhibition by Lisofylline was not found to be similar to that of
Caffeine or Theobromine.

This finding indicates that the 5-Hydroxyhexyl

substituent on Lisofylline substantially reduces binding to PrAO.

3.4.2 Modelling of Caffeine, Theobromine and Theophylline interactions
with PrAO
In view of the noncompetitive pattern of binding observed in this study for
Theobromine (Fig 3.41) and by Olivieri and Tipton (2011) for caffeine it was of
interest to investigate their binding site(s) on PrAO. A computational approach
was employed using AutoDock software 4.0 in an attempt to identify possible
methylxanthine binding sites. A computational model for Bovine PrAO was
constructed as described in Section 2.9. The top ranking scores (the more negative
the ranking value the more energetically favorable the binding) and binding
interactions between molecule and PrAO residue side chains are detailed.

Computational docking of theobromine, caffeine and theophylline were
investigated to broaden our understanding of the binding interaction between these
compounds and PrAO. Figure 3.44 is a molecular surface computational model
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showing predicted binding of theobromine near the active site entrance of PrAO.
Figure 3.45 is a stick model representation showing potential binding interactions
between theobromine and PrAO residues in greater detail. Figures 3.46 and 3.47
show a similar exercise carried out for binding of caffeine to PrAO while Figures
3.48 and 3.49 show theophylline binding depicted in the same manner. Caffeine
has not been previously computationally modeled for its binding with PrAO and
is a useful comparison to theobromine for binding interactions. Theophylline is a
useful comparator here since it did not inhibit PrAO to the same degree as either
theobromine or caffeine.

For each compound, a surface molecular image is shown to illustrate binding
interactions and show the location of the ligand on the enzyme surface. Also shown
is a stick model image to illustrate the binding interactions with PrAO side chains.
Relevant amino acid side chains are labelled to highlight the active site entrance
location and binding interactions. The software computes binding affinity at
different sites as a numerical score. A summary table can be found below detailing
inhibition and binding interactions (see Table 3.2).
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Fig. 3.44. A molecular surface representation with polarity shading is depicted for the docking
interaction of Theobromine and PrAO. Theobromine is shown as a stick structure binding to the
surface of PrAO. Docking of Theobromine had a top rank docking score of -2.59 (Gbind) as
calculated by AutoDock Tools 1.5.6. The diagram indicates the active site entrance of PrAO and
binding location of theobromine. Gate-acting Leu468, Asn469 and Pro237 residues are highlighted
at or near the active site entrance. Polar regions are indicated in blue for positively charged, and
red for negatively charged residues. Hydrophobic residues are indicated in in grey.

Fig. 3.45. A computational stick model representation of Figure 3.44. Image A (center) depicts
theobromine, shown in grey, bound to the enzyme in close proximity to the active site entrance.
Image B is a magnification of the binding interaction of image A showing polar regions in blue
for positively charged and red for negatively charged residues. The grey shading indicates
hydrophobic regions. Image C shows the removal of the surface which better depicts potential
hydrogen bonding between the carbonyl group of theobromine and the amine group of Asn469 by
a green line of spheres.
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Fig. 3.46. Caffeine had a top rank docking score of -2.30 (Gbind) as calculated by AutoDock Tools
1.5.6 when bound to PrAO. A molecular surface representation with polarity shading is depicted
for the docking interaction of ligand and macromolecule, indicating the active site entrance of
PrAO and binding location of caffeine. Asn469, Thr466 and Arg173 are highlighted at or near the
active site entrance. Polar regions are indicated by blue, positively charged and red negatively
charged, binding interactions. The grey shading depicts hydrophobic interactions.

Fig. 3.47. A computational stick model representation of Figure 3.46. Image A depicts caffeine,
shown in grey, to be externally bound to the enzyme in close proximity to the active site entrance.
Image B is a magnification of the binding interaction of image A, depicting polarity regions as
blue for positively charged and red for negatively charged binding interactions. The grey indicates
hydrophobic regions. Image C is the removal of the surface representation, which better depicts
hydrogen bonding between the carbonyl group of caffeine and the amine group of Asn469 by a
green line of spheres.
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Fig. 3.48. Theophylline had a top rank docking score of -2.75 (Gbind) as calculated by AutoDock
Tools 1.5.6 when bound to PrAO. A molecular surface representation with polarity shading is
depicted for the docking interaction of ligand and macromolecule, indicating the active site
entrance of PrAO and binding location of theophylline. Asn469 and Arg173 are highlighted at or
near the active site entrance. Polar regions are indicated by blue for positively charged, red for
negatively charged binding interactions.

Fig. 3.49. A computational stick model of Fig. 3.48. Image A shows theophylline, shown in grey,
to be externally bound to the enzyme in close proximity to the active site entrance. Image B is a
magnification of the binding interaction of image A, depicting polarity regions such as blue for
positively charged and red for negatively charged binding interactions. The grey indicates
hydrophobic regions. Image C is the removal of the surface representation, which better depicts
hydrogen bonding shown by a green line of spheres between the amine group of theophylline and
the amine group of Leu468, while giving a better visual of the ligand and interacting side chains
involved.
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Table 3.2. Summary of binding interactions for selected Methylxanthines with PrAO,
predicted by AutoDock.

Docked
Compound
Theobromine

Observed
PrAO
Inhibition
Yes

Docking
Score
(Gbind)
-2.59

Hydrogen
Bonding
Asn469

Hydrophobic
Interactions
Tyr238
Leu468
Pro237

Caffeine

Yes

-2.30

Asn469

Leu468
Pro237

Theophylline

No

-2.75

Leu468

Leu468

An overview of methods and findings of methylxanthines and related structures
that were tested for PrAO modulation can be found below (see Figure 3.50).

Fig. 3.50. Overview of main findings observed and methods used in the testing of
methylxanthine and related compounds assayed for PrAO modulation.
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3.5

Amino Acids

An interest in screening amino acids was based upon previous work in this lab,
namely the inhibition of PrAO by lysine in the presence of H2O2. As lysine
inhibited PrAO structurally related amino acids such as ornithine and L-arginine
(Fig. 3.54 and 3.56) were screened for similar inhibitory effects. Cysteine, an
amino acid with a thiol group yielded significant inhibition (Fig. 3.52), Dethionine also having a thiol group (Fig. 3.55) was screened with no inhibition
evident. Other similar short chained amino acids were appropriate to screen, for
example; the thiol group of cysteine was replaced with a hydroxyl group of Dserine (Fig. 3.57.) or methyl groups of D-norvaline (Fig. 3.53.). In an aligned substudy, alanine, iso-leucine, threonine and phenylalanine were also tested. A full
list of test results can be found in Table 3.3. These amino acid structures are
depicted in Fig. 3.51. All data were obtained using the UV plate reader
spectrophotometric assay (see section 2.5) monitoring the product benzaldehyde.
The concentrations of amino acids tested for inhibition were 1.0 mM and 100 μM
to verify potential physiologically relevant inhibition.

Fig. 3.51. Chemical structures of selected amino acids. http://www.chemspider.com/Chemical-Structure.
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3.5.1 L-cysteine
L-cysteine inhibition assay of PrAO (Fig. 3.50) revealed a significant difference
between treatments and the control using ANOVA (P ≤ 0.001). Although there
was a significant difference between the lower concentration of L-cysteine (100
μm) and the control, the higher concentration (100 mM) was not significantly
different to the control (P > 0.05; Fig. 3.50).
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Fig. 3.52. L-cysteine inhibition assay of PrAO with blank, control, inhibition
control and experimental assay with 1 mM and 100 μM concentrations. Assays
were performed at 254 nm monitoring benzaldehyde production in triplicate.
Positive controls with PrAO and substrate and negative inhibition controls with
PrAO, substrate and 1 mM semicarbazide were included. An asterisk denotes a
significant difference between treatments and the control (***P ≤ 0.001) using
ANOVA and Dunnett’s test.
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3.5.2 D-norvaline
D-norvaline significantly inhibited at a concentration of 1.0mM (*P ≤ 0.05) PrAO
(Fig. 3.51).

Fig. 3.53. D-norvaline inhibition assay of PrAO with blank, control, inhibition control and
experimental assay with 1 mM and 100 μM concentrations of. Assays were performed at 254 nm
monitoring aldehyde production and in triplicate. Positive controls with PrAO and substrate and
negative inhibition controls with PrAO, substrate and 1 mM semicarbazide were included. An
asterisk denotes a significant difference between treatments and the control (*P ≤ 0.05) using
ANOVA and Dunnett’s test.
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A c t iv it y ( % m e a n  S E )

3.5.3 Ornithine
Ornithine inhibition assay of PrAO (Fig. 3.52) revealed a slight decrease in the
activity rate (mAbs/min); however, neither the 100 μm or 1 mM of ornithine
significantly inhibited PrAO (P > 0.05; Fig. 3.52).
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Fig. 3.54. Ornithine inhibition assay of PrAO with blank, control, inhibition control and
experimental assay with 1 mM and 100 μM concentrations. Assays were performed at 254 nm
monitoring aldehyde production and in triplicate.

3.5.4 D-ethionine

A c t iv it y ( % m e a n  S E )

D-ethionine did not significantly inhibit PrAO (P > 0.05; Fig. 3.53).
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Fig. 3.55. D-ethionine inhibition assay of PrAO with blank, control, inhibition control and experimental
assay with 1 mM and 100 μM concentrations of D-ethionine. Assays were performed at 254 nm monitoring
aldehyde production and in triplicate. Positive controls with PrAO and substrate and negative inhibition
controls with PrAO, substrate and 1 mM semicarbazide were included.
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3.5.5 L-arginine

A c t iv it y ( % m e a n  S E )

L-arginine did not significantly inhibit PrAO (P > 0.05; Fig. 3.54).
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Fig. 3.56. L-arginine inhibition assay of PrAO with blank, control, inhibition control and experimental assay
with 1 mM and 100 μM concentrations. Assays were performed at 254 nm monitoring aldehyde production
and in triplicate. Positive controls with PrAO and substrate and negative inhibition controls with PrAO,
substrate and 1 mM semicarbazide were included.
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3.5.6 D-serine
The D-serine inhibition assay of PrAO (Fig. 3.55) exhibited a slight decrease in
PrAO activity (mAbs/min) but did not significantly inhibit PrAO (P > 0.05; Fig.
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3.55).
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Fig. 3.57. D-serine inhibition assay of PrAO with blank, control, inhibition control and
experimental assay with 1 mM and 100 μM concentrations. Positive controls with PrAO and
substrate and negative inhibition controls with PrAO, substrate and 1 mM semicarbazide were
included.
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3.6

Vitamins as PrAO modulators

As discussed in Chapter 1 Section 1.8, vitamins are being actively researched for
their specific health benefits in numerous diseases such as cancer and diabetes, and
therefore have relevance in being tested as natural dietary inhibitors for PrAO
modulation. Thiamine (Vitamin B1) and Pyridoxine (Vitamin B6) (Fig. 3.58)
showed statistically significant inhibition when tested using the Holt method
monitoring H2O2 production as described in Section 2.5.1. IC50 values, patterns of
inhibition and Ki values were determined for each inhibitor. A full list and results
of all vitamins tested can be found in Table 3.3.

Fig. 3.58. Chemical structure of thiamine and pyridoxine.
http://www.chemspider.com/Chemical-Structure
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3.6.1 Thiamine
The thiamine inhibition of PrAO (Fig. 3.57) revealed a significant difference
between treatments using ANOVA (P ≤ 0.01). Fig. 3.58 exhibits the IC50 inhibition
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of thiamine and Fig. 3.59. depicts the Lineweaver Burk plots of thiamine.
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Fig. 3.59. Thiamine inhibition assay of PrAO with blank, control, inhibition control and
experimental assay with 1 mM and 0.5 mM concentrations. Assays were performed at 498 nm
monitoring H2O2 production in triplicate. Positive controls with PrAO and substrate and negative
inhibition controls with PrAO, substrate and 1 mM semicarbazide were included. An asterisk
denotes a significant difference between treatments and the control (**P ≤ 0.01) using ANOVA
and Dunnett’s test.
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R2 0.986

Fig. 3.60. Thiamine IC50 inhibition plot showing log concentration of inhibitor Vs % activity,
giving an IC50 of 5.046 mM ±1.15 mM. Inhibitor concentration ranged from 0.1 mM to 50 mM
and substrate concentration of 5 mM benzylamine. Data shown are the mean values ± SEM, error
bars not evident were less than the representation of the points. Assays were performed in triplicate
and IC50 readings gained at 498 nm at 37°C and pH 7.2. Data were fitted with non-linear regression
analysis with the aid of computer soft- ware GraphPad Prism, 5.0.
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Fig. 3.61. Substrate (benzylamine) patterns of inhibition of PrAO by thiamine. A competitive type
pattern of inhibition is observed. All samples contained increasing concentrations of thiamine
(from 0.25 mM to 2.5 mM) and benzylamine (from 1 to 5 mM). Data shown are the mean values
± SEM, error bars not evident were less than the representation of the points. The initial rates (v =
abs498 nm × 10−3 min) of hydrogen peroxide formation were determined at 37◦C and pH 7.2. Data
were fitted to the Michaelis–Menten equation with the aid of computer soft- ware GraphPad Prism,
5.0.
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3.6.2 Pyridoxine
Pyridoxine significantly inhibited PrAO at 0.5 mM (P ≤ 0.01) and 1 mM (P ≤
0.001; Fig. 3.62). Fig. 3.63 exhibits the IC50 inhibition plot of pyridoxine and Fig.
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3.64 depicts the pyridoxine Lineweaver Burk plots.
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Fig. 3.62. Pyridoxine inhibition of PrAO with a control, inhibition control and experimental assay
with 1.0 mM and 0.5 mM concentrations. Assays were performed at 498 nm monitoring H2O2
production in triplicate. Positive controls with PrAO and substrate and negative inhibition controls
with PrAO, substrate and 1 mM semicarbazide were included. An asterisk denotes a significant
difference between treatments and the control (**P ≤ 0.01; ***P ≤ 0.001) using ANOVA and
Dunnett’s test.
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Fig. 3.63. Pyridoxine IC50 inhibition plot showing log concentration of inhibitor Vs % activity,
giving an IC50 of 5.55 mM ± 2.81 mM. Inhibitor concentration ranged from 125 mM to 25 mM
and substrate concentration of 5 mM benzylamine. Data shown are the mean values ± SEM, error
bars not evident were less than the representation of the points. Assays were performed in triplicate
and IC50 readings gained at 498 nm at 37°C and pH 7.2. Data were fitted with non-linear regression
analysis with the aid of computer soft- ware GraphPad Prism, 5.0.
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Fig. 3.64. Substrate (benzylamine) pattern of inhibition of PrAO by pyridoxine. An un-competitive
type pattern of inhibition is observed. All samples contained increasing concentrations of
pyridoxine (from 0.125 mM to 2.5 mM) and benzylamine (from 1 to 5 mM). Data shown are the
mean values ± SEM, error bars not evident were less than the representation of the points. The
initial rates (v = abs498 nm × 10−3 min) of hydrogen peroxide formation were determined at 37◦C
and pH 7.2. Data were fitted to the Michaelis–Menten equation with the aid of computer soft- ware
GraphPad Prism, 5.0.
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3.8 Non-dietary Xenobiotics as PrAO inhibitors
A selection of xenobiotic compounds such as benzylhydrazine, 4-amino-phenol
and acrylamide were tested to further the knowledge of structures that may inhibit
PrAO. These compounds were selected due to either having primary amines or
being structurally similar to other compounds with some potential to be PrAO
modulators. A summary these results can be found in Table 3.4. Benzylhydrazine
(Fig. 3.65) was the only compound tested that showed statistically significant
inhibition (Fig. 3.66). Additional experimentation was performed on this
compound and the corresponding results are detailed below in bar graph form with
IC50 values, patterns of inhibition. Benzylhydrazine significantly inhibited PrAO
at 1.0 nM and 4.0 nM (P ≤ 0.001; Fig. 3.66). IC50 inhibition plot of
benzylhydrazine is displayed in Fig. 3.67, the Lineweaver Burk plot of
benzylhydrazine is exhibited depicting probable mode of inhibition in Fig. 3.68.

Fig. 3.65. Chemical structure of benzylhydrazine.
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Fig. 3.66. Benzylhydrazine inhibition assay of PrAO with blank, control, inhibition control and
experimental assay with 1 nM and 4 nM concentrations. Assays were performed at 254 nm
monitoring aldehyde production in triplicate. Positive controls with PrAO and substrate and
negative inhibition controls with PrAO, substrate and 1 mM semicarbazide were included. Result
show a significant difference, denoted by an asterisk (***P ≤ 0.001) using ANOVA and Dunnett’s
post hoc analyses.
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Fig. 3.67. Benzylhydrazine IC50 inhibition plot showing log concentration of inhibitor Vs %
activity, giving an IC50 of 6.628 nM ±3.2 nM. Inhibitor concentration ranged from 0.5 nM to 25
nM 25 mM and substrate concentration of 5 mM benzylamine. Data shown are the mean values ±
SEM, error bars not evident were less than the representation of the points. Assays were performed
in triplicate and IC50 readings gained at 498 nm at 37°C and pH 7.2. Data were fitted with nonlinear regression analysis with the aid of computer soft- ware GraphPad Prism, 5.0.
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Fig. 3.68. Substrate (benzylamine) patterns of inhibition of PrAO by benzylhydrazine. An uncompetitive type pattern of inhibition is observed. All samples contained increasing concentrations
of benzylhydrazine (from 0.125 mM to 2.5 mM) and benzylamine (from 1 to 5 mM. Data shown
are the mean values ± SEM, error bars not evident were less than the representation of the points.
The initial rates (v = abs498 nm × 10 −3 min) of hydrogen peroxide formation were determined at
37◦C and pH 7.2. Data were fitted to the Michaelis–Menten equation with the aid of computer
soft- ware GraphPad Prism, 5.0.
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Table 3.3. Summary table of various compounds tested for significance of inhibition of
PrAO at 254 nm for benzaldehyde production. Compounds in each category are presented
in order of significance with P values attached.
Compound

Type

Concentration
(mM)

Significance of
inhibition vs.
control

P value

Caffeine Analogs
Caffeine

Endogenous

1.00

***

≤ 0.001

Theobromine

Endogenous

1.00

***

≤ 0.001

Caffeic acid

Endogenous

1.00

***

≤ 0.001

Theophylline

Endogenous

1.00

**

≤ 0.01

7-Methylxanthine

Endogenous

1.00

**

≤ 0.01

§

Lisofylline

Xenobiotic

1.00

**

≤ 0.01

Paraxanthine

Endogenous

1.00

**

≤ 0.01

Xanthine

Endogenous

1.00

N/S

≤ 0.05

Tryptamine

Endogenous

1.00

**

≤ 0.01

8-Bromocaffeine

Endogenous

1.00

N/S

> 0.05

Adenine

Endogenous

1.00

N/S

> 0.05

Uric acid

Endogenous

1.00

N/S

≤ 0.05

Nicotinamide

Endogenous

1.00

N/S

> 0.05

Adenosine

Endogenous

1.00

N/S

> 0.05

Imidazole

Endogenous

1.00

*

≤ 0.01

1-Methyl-L-histidine

Endogenous

1.00

N/S

> 0.05

1-Methylimidazole

Endogenous

1.00

N/S

> 0.05

Epigallocatechin gallate

Endogenous

0.02

***

≤ 0.001

Epicatechin gallate

Endogenous

0.025

***

≤ 0.001

§ Quercetin

Endogenous

0.05

***

≤ 0.001

Epicatechin

Endogenous

0.68

N/S

> 0.05

Catechol

Endogenous

0.68

N/S

> 0.05

Rutin

Endogenous

1.00

N/S

≤ 0.05

Methyl gallate

Endogenous

0.05

N/S

≤ 0.05

Gallic acid

Endogenous

0.05

N/S

≤ 0.05

Diazole

Phenols
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Amino acids
L-cysteine

Endogenous

1.00

***

≤ 0.001

D-norvaline

Endogenous

1.00

*

≤ 0.05

L-ornithine

Endogenous

1.00

N/s

≤ 0.05

D-ethionine

Endogenous

1.00

N/s

> 0.05

L-arginine

Endogenous

1.00

N/S

> 0.05

Pyrocatechol

Endogenous

1.00

N/S

> 0.05

Phenylalanine

Endogenous

1.00

N/S

> 0.05

L-alanine

Endogenous

1.00

N/S

> 0.05

D-serine

Endogenous

1.00

N/S

> 0.05

D-Iso-leucine

Endogenous

1.00

N/S

> 0.05

Cystic acid

Endogenous

1.00

N/S

> 0.05

§

Endogenous

1.00

**

≤ 0.01

§

Endogenous

1.00

**

≤ 0.01

§

Endogenous

1.00

N/S

> 0.05

§

Endogenous

1.00

N/S

> 0.05

§

Endogenous

1.00

N/S

> 0.05

Umbelliferone

Endogenous

1.00

***

≤ 0.001

Octopamine

Endogenous

1.00

**

≤ 0.01

GABA

Endogenous

1.00

N/S

> 0.05

§

Trigonelline

Endogenous

1.00

N/S

> 0.05

Ethanolamine

Endogenous

1.00

N/S

> 0.05

Benzylhydrazine

Xenobiotic

0.004

***

≤ 0.001

4-amino-phenol

Xenobiotic

1.00

N/S

> 0.05

2 Chloromethyl
benzimidazole

Xenobiotic

1.00

N/S

> 0.05

Sulphanilamide

Xenobiotic

1.00

N/S

> 0.05

4-acetoamidophenol

Xenobiotic

1.00

N/S

> 0.05

Tetrabenzine

Xenobiotic

1.00

N/S

> 0.05

Acrylamide

Xenobiotic

1.00

N/S

> 0.05

Vitamins
Pyridoxine
Thiamine (B1)
Ascorbic Acid
Vitamin B12
Riboflavin (B2)

Dietary Endogenous

Non-dietary Xenobiotic

Note: § represents activity being monitored at 498 nm.
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Table 3.4. Summary table of various inhibitors tested using the standard plate reader
colourimetric assay at 498 nm, where IC50 and Ki values were obtained.
Compound

Type

Concentration
Range

IC50
Value

Mode of
Inhibition

Ki Value

Benzylhydrazine

Non-endogenous
primary amine

0.5 – 25 nM

6.628 nM

non-competitive

N/A

Endogenous flavonoid

10 – 500 μM

52.2 μM

N/A

N/A

Theobromine

Xanthine

0.1 – 5 mM

427.9 μM

uncompetitive

275.6 μM

Octopamine

Endogenous trace
amine

0.1 – 100 mM

3.26 mM

mixed mode

N/A

Thiamine

Endogenous dietary
supplement (Vit-B1)

0.1 – 50 mM

5.046 mM

competitive

N/A

Pyridoxine

Endogenous dietary
supplement (Vit-B6)

0.125 – 25 mM

5.55 mM

non-competitive

N/A

Quercetin
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3.7

Summary

In summary, the most significant findings were that theobromine and caffeine were
the only methylxanthines to inhibit in the micromole range from the selection of
methylxanthines and related compounds tested. Potential binding site and residue
interactions were modelled with the aid of computational modelling software and
showed a possible interaction at the base of the active site entrance funnel.
Epigallocatechin gallate and epicatechin gallate could not be excluded as PrAO
inhibitors but their assessment was complicated by non-enzymatic reactions that
gave rise to ill-defined products.

A selection of amino acids, vitamins and xenobiotics were screened showing
lysine and cysteine being the only significant inhibitors of PrAO. Other significant
inhibition was observed with pyridoxine and thiamine, octopamine and quercetin
along with the xenobiotic benzylhydrazine.
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CHAPTER 4
4

Discussion
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4.0

General Introduction

In Chapter 1 the important role played by PrAO in a wide range of diseases such as
diabetes, cancer and vascular disease was described in depth. There are few proteins
in the body that play a key role in such a wide range of disease processes. A large
number of studies in animals have shown that inhibition of this enzyme has the ability
to positively affect inflammation, cancer progression and vascular damage (Becchi et
al., 2017; Kinemuchi et al., 2004a; Wang et al., 2018). In the present study we
explored the possibility that components present in the diet might influence PrAO
activity. Therefore, we decided to look at bioactive compounds in plants that might
have a protective effect on health through their inhibition of PrAO. Dietary
methylxanthines and phytochemicals from green tea were the main focus of our efforts
along with selected amino acids and vitamins.

The location of PrAO on the vascular endothelium (Hafezi-Moghadam, 2018) means
it will come in contact with absorbed dietary compounds and their breakdown products
as well as endogenous effectors and xenobiotics. This research focused on identifying
molecules with known bioactive properties that could modulate PrAO activity.

4.1

Methylxanthines in PrAO Inhibition

Previous work in this laboratory, in collaboration with a group in Trinity College
Dublin, showed caffeine to be a modulator of bovine PrAO although not a potent
inhibitor with a Ki of 1.0mM (Olivieri and Tipton, 2011). This work was followed up
by a laboratory in China who looked at the effect of caffeine consumption on PrAO
activity in vivo using a rat model. They showed that caffeine could reduce PrAO
activity in vivo and suggested that caffeine might be useful as a therapeutic for
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lowering PrAO activity. This finding prompted us to explore the possibility that other,
structurally related, methylxanthines might inhibit PrAO. Caffeine is one of several
methylxanthines present in the diet and it is metabolized to a range of metabolites
whose action against PrAO had not been explored. Caffeine analogs that were
examined in this study were theophylline, theobromine, 7 methylxanthine and
paraxanthine as well as a variety of related compounds that represented components
of those structures. The objective was to attempt to identify structural features required
for inhibition of PrAO.

Methylxanthines structurally contain two coupled rings: a pyrimidinedione ring and
an imidazole ring (Zacharis et al., 2013).
Theophylline (1,3-dimethylxanthine; Fig. 3.34) is a metabolite of caffeine (1,3,7trimethylxanthine; Santos et al., 2015) and is found in cocoa and tea (Martínez-López
et al., 2014). Theophylline has been used as a therapeutic for asthma, acting as a
bronchodilator (Cosío et al., 2016) and is used in the treatment of respiratory diseases
such as chronic obstructive pulmonary disease (Kirkham et al., 2014). This compound
inhibited PrAO by approximately 20%, at 1.0 mM compared to caffeine which
inhibited PrAO by ca. 60% at the same concentration (see Fig. 3.35).

Since theophylline and caffeine differ only by a single methyl group at position 7 on
the imidazole ring it was clear that methylation at this point was important for
inhibition and that the diazole moiety of xanthine could play a role in PrAO inhibition.
We examined a number of diazoles (imidazole, 1-methyl-L-histidine and 1methylimidazole; see Fig. 3.39) at a 1.0 mM concentration and they showed little or
no inhibition of PrAO (Fig. 3.38). These observations indicated that the entire xanthine
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molecule was required for inhibition with the position and number of methyl groups
playing an important role.

The methylxanthines; 7-methylxanthine, theobromine, and paraxanthine (Fig 3.34)
along with xanthine nucleus (Fig. 3.37) were examined for inhibition of PrAO (see
below Fig. 4.1). Of these, it was found that theobromine inhibited PrAO activity to
approximately 30% at 1 mM. The theobromine data showed that N-methyl groups
were critical for inhibition (see Fig. 3.35 and Fig. 3.36). It was clear that a
methylxanthine with N-methylation at positions 3 and 7 was required for significant
inhibition of PrAO. The presence of a methyl group in position 1, as in caffeine,
seemed to decrease the inhibitory effect presumably for reasons of steric hindrance.

Fig. 4.1. Caffeine structure showing the N-methyl groups numbered around the xanthine nucleus.

Theobromine showed an IC50 value of 427.9 μM +/- 100 μM (Fig. 3.40) and a Ki of
276 µM +/- 32 µM (Fig. 3.41). Thus, it was clear that Theobromine was a more potent
inhibitor than caffeine with a reported IC50 value of 800 μM +/- 300 μM and a Ki value
of 1.0 mM. Of the methylxanthines we examined, theobromine was the only one more
potent than caffeine for PrAO inhibition.
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This is of particular interest since

theobromine, as well as being present in high amounts in dark chocolate among other
sources, is a metabolite of caffeine (See Fig. 4.2).

Fig. 4.2. The metabolites of caffeine in vivo are shown. These metabolites are generated by removal of
a methyl group from caffeine.

Since theobromine was the most potent methylxanthine found to date associated with
PrAO inhibition we looked at the pattern of inhibition by measuring the Km for
benzylamine in the presence of increasing concentrations of theobromine. A
noncompetitive pattern was observed (Fig. 3.41). This pattern consists of a series of
lines all intersecting on the horizontal axis. Such a pattern shows that the Km for the
substrate benzylamine was not changed by the presence of the inhibitor but Vmax was
altered. This type of inhibition is interpreted as indicating that the presence of the
inhibitor does not influence the binding of substrate but does influence the catalytic
rate (Fig. 4.3).
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Fig. 4.3. Mechanism of noncompetitive Inhibition. The Enzyme (E) can bind substrate (S) to form an
ES complex which, after catalysis, releases product (P). The scheme also shows that inhibitor (I) can
bind to both the enzyme (E) and the ES complex. Thus, the binding of substrate does not prevent the
binding of inhibitor (their binding sites do not overlap). Such a mechanism will give rise to a pattern of
lines intersecting on the horizontal axis.

A similar inhibition pattern was observed for caffeine with benzylamine as substrate
(Olivieri and Tipton, 2011). Therefore, this inhibition pattern clearly shows there is a
site on the surface of PrAO that can interact with both of the methylated nitrogen
moieties of theobromine and caffeine.

In humans the plasma concentration of theobromine has been reported to be as high
as 63 μM following the consumption of chocolate (Oñatibia-Astibia et al., 2017).
Taking the Ki as 276 μM we can calculate the effect on PrAO of levels of theobromine
as high as 63 μM using the relationship between Ki and inhibitor concentration for a
noncompetitive inhibitor given by equation 1:

𝑉𝑚𝑎𝑥 𝑎𝑝𝑝 =

𝑉𝑚𝑎𝑥
𝐼
1 + 𝐾𝑖

Equation 1. Noncompetitive inhibition: The relationship between maximum velocity (Vmax app, - the
apparent maximum velocity) in the presence of an inhibitor (I) and the maximum velocity in the
absence of an inhibitor (Vmax). The term Ki refers to the inhibitor binding constant.
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Using a figure of 63 μM for [I] and 276 μM for Ki we can calculate that the maximum
rate in the presence of this concentration of inhibitor is reduced by approximately 20%.
This suggests that a plasma concentration of theobromine of 63 μM could reach levels
in vivo sufficient to inhibit PrAO by roughly 20%, which may be sufficient to influence
associated diseases (see chapter 1, section 1.6 and 1.7).

The finding that Theobromine and caffeine bind at a site other than the active site on
PrAO was particularly interesting. This meant that there was a site that could influence
activity that was separate to the active site. This had not been reported before. These
studies showed that the N-methylation at positions 3 and 7 were important for
inhibition.

Interestingly, imidazoline binding sites for PrAO have been described through X-ray
crystallography of two bound molecules: clonidine (Holt et al., 2008) and imidazole
(Elovaara et al., 2011). Clonidine an inhibitor of bovine PrAO, is shown to undergo
pi-stacking with the aromatic rings of TPQ and Tyr472 forcing TPQ into an inactive
“on state” bound to the copper atom in the active site whereby the deamination of
primary amines cannot occur (Holt et al., 2008b). It seems unlikely that the N-methyl
groups described here would interact in the same manner but cannot be fully excluded.
In another study it was found that imidazole could form hydrogen bonds to TPQ in the
inactive on-state conformation (see Fig. 1.6). A second imidazoline binding location
was also identified in the substrate channel where imidazole bound to Tyr394 and
Thr212 (Elovaara et al., 2011). It is possible that this site might be involved in
theobromine binding but the interaction with imidazole was much weaker than that for
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theobromine. Additionally, computational modeling of theobromine binding to PrAO
in this study did not indicate any involvement in binding (see Section 4.2).

None of the other related caffeine-related compounds tested showed significant
inhibition (Chapter 3, Fig. 3.36). For example, neither 8-bromocaffeine, nor Uric Acid
could significantly inhibit PrAO, despite structural similarity to xanthine (one more
carboxyl group on the imidazole ring). Closely related purine molecules adenine and
adenosine were also examined since they have similar structures to caffeine except for
having no amides in the ring structures: these also resulted in no significant inhibition
of PrAO. These findings all indicate that the xanthine structure alone cannot be the
main cause of PrAO inhibition. Inhibition requires specific methyl groups at specific
locations around the structure to have maximum inhibitory effect.

4.1.2. PrAO inhibition by Lisofylline
Lisofylline is a methylxanthine-derived small molecule with anti-inflammatory
properties that may be useful in treatment of type 1 diabetes (Fig. 4.4).

Fig. 4.4. The structure of lisofylline (left) compared to caffeine (right). Lisofylline is similar to caffeine
but where caffeine has a methyl group (CH 3) at position 1 lisofylline has a bulky hydroxyhexyl group.

The exact mechanism of action of lisofylline is not known. Given its structural
similarity to caffeine it seemed likely that it might inhibit PrAO. We reasoned that if
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it were a PrAO inhibitor it would provide a link between this drug and a molecular
target. At a concentration of 1 mM, Lisofylline yielded significant inhibition (25%,
Fig. 3.42). However, it was a poorer inhibitor than caffeine. We can conclude that the
increased bulk at position 1 is leading to this loss in potency. Thus, theobromine with
no substituent at position 1 is a better inhibitor than caffeine which has a methyl group
at position 1. Lisofylline, with an even larger substituent at position 1, is even poorer
than caffeine as a PrAO inhibitor. Thus, it is unlikely that the mechanism of action of
this drug in vivo involves modulation of PrAO activity.

4.2

Computational Docking of Methylxanthines to PrAO

In an attempt to get a better understanding of the site of interaction between PrAO and
inhibitors we constructed an in silico model of PrAO and looked at molecular docking
of methylxanthines onto the enzyme. The software output ranks candidate dockings
assigning a docking score to each binding mode.

The computational docking findings for caffeine, theobromine and theophylline all
produced a rank-1 binding docking score for these compounds to a site at the base of
the PrAO active site entrance funnel. Docking poses are computed for the most energy
efficient binding per docking pose interaction as explained in chapter 2, section 2.9.
The more negative the docking score the more efficient binding is predicted for that
particular docking location.
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4.2.1 Computational Docking Interactions with Theobromine, Caffeine and
Theophylline
Theobromine had a rank 1 docking score of -2.59 (Gbind). Hydrogen bonding is
predicted between the carbonyl group of theobromine the heterocyclic aromatic amine
of Asn469 on PrAO (Fig. 3.45). Hydrophobic interactions are predicted between
Tyr238, Leu468 and Pro237. Caffeine had a rank 1 docking score of -2.30 (Gbind)
and is similarly involved in a hydrogen bond formation with amide group of Asn469
(Fig. 3.47). Hydrophobic interactions were predicted between Leu468 and Pro237.

Theophylline, which also bound near the active site, had the most energetically
favourable docking score of -2.75 (Gbind). Hydrogen bonding was predicted between
the heterocyclic aromatic amine of theophylline and the carbonyl group of the side
chain residue Leu468 (Fig. 3.49). Table 3.2 highlights the important residues involved
in hydrogen binding with methylxanthines, Asn469 and Leu468, while for
hydrophobic interactions residues Pro237 and Leu468 are prominent along with
Tyr238.

4.2.2

Computational modelling of PrAO Inhibition by Theobromine, Caffeine
and Theophylline

In vitro assays had shown that caffeine and theobromine inhibited PrAO, while
theophylline had little or no inhibition. Common hydrogen binding patterns predicted
for the two most significant methylxanthines (caffeine and theobromine) showed an
interaction with Asn469 and with both carbonyl groups of theses methylxanthines in
the same position, showing the importance of this group in hydrogen bonding
interactions with Asn469 of PrAO. Asn469 is located internally in the active site, but
is also part of the external wall structure.
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Asn469 has significance in bovine PrAO catalysis where it is required to rotate away
from the internal pocket and face the mouth of the entrance channel to permit substrate
docking (Holt et al., 2008b). The binding of caffeine and theobromine to Asn469 may
hinder this rotation, preventing substrate from interacting with the TPQ co-factor.

Leu468 is understood to act like a gate-controlling side chain as discussed in chapter
1, section 1.3.1. It is located at the active site entrance and therefore has a significant
effect on substrate access. From the computational modelling data for theophylline, it
is possible that binding to Leu468 may keep the side chain in the open position and
therefore not interfere with substrate access or catalysis in the active site.

Theobromine has greater hydrophobicity than caffeine (see Section 1.8.1);
theobromine

displays

a

0.5mg/mL

solubility

concentration

in

H2 O

(https://pubchem.ncbi.nlm.nih.gov/compound.ncbi.nlm.nih.gov/compound/2519#sec
tion=Melting-Point), which could indicate that theobromine might preferentially bind
in the hydrophobic pocket at the base of the PrAO active site funnel. Docking studies
for theobromine and caffeine (Fig. 3.44 and 3.46) show that these ligands are bound
near the active site entrance in a predominantly hydrophobic pocket. Hydrophobic
interactions for both caffeine and theobromine in this pocket are reported to be with
Tyr238, Leu468 and Pro237 (See Table 3.2). These interactions may account for the
greater affinity and potency observed in the docking score for these compounds and
help to explain the experimental findings for theobromine inhibition compared to
caffeine.
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4.2.3 Methylxanthines Summary
We have shown for the first time that theobromine is an inhibitor of PrAO. It is more
effective than caffeine. Comparing the structures of compounds that significantly
inhibited PrAO against those that did not, we were able to identify N-methylation at
positions 3 and 7 of the xanthine nucleus as necessary for inhibition. We further
showed that the presence of bulky substituents at position 1 caused inhibition to
decrease. Both caffeine and theobromine were found to inhibit PrAO significantly in
the micromole range: computational docking predicted the importance of positions 3
and 7 containing methyl groups thereby allowing the carbonyl group contained
between these positions to be involved in hydrogen bonding to Asn469.

Theophylline with methyl groups at positions 1 and 3, hydrogen bonding occurred
with the free amine at position 7 and with the amino group of the PrAO residue
Leu468. This then leads to the hypothesis that it is crucial for positions 3 and 7 on the
xanthine structure to have methyl or possibly other functional groups to have a notable
inhibitory effect on PrAO.

4.3

Inhibition of PrAO by polyphenols

Polyphenols have shown great potential in treating diseases such as cancer, diabetes,
inflammation and obesity (Chen et al., 2011; Chacko et al., 2010; Wang et al., 2014).
Our interest in screening polyphenols as potential inhibitors of PrAO was underpinned
by reported health benefits for these compounds especially the correlation noted
between the health benefits of dietary polyphenols and PrAO-associated disease.
Many of the diseases correlated with abnormal PrAO activity such as cancer, diabetes,
inflammation, heart disease, Parkinson’s disease and obesity (Chacko et al., 2010;
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Hara, 2001; Schneider and Segre, 2009; Sinija and Mishra, 2008) are also targets of
polyphenols.

4.3.1 Green Tea
A crude extract of undiluted green tea was initially assayed to explore any modulatory
effects that green tea might have on PrAO activity. In our initial trial experiments
green tea extract resulted in a large increase in PrAO activity rates. When the extract
was diluted 1:100 instead of a leveling of rates compared to the control, which would
have been expected, inhibition of PrAO was evident (Fig. 3.7). Inhibition at low
concentrations of an inhibitor followed by activation at high concentrations was an
obviously anomalous finding. There is no simple mechanism whereby binding at a
single site on an enzyme can give rise to inhibition at low concentrations and activation
at high concentrations.

One possibility was that individual components of the Green tea extracts might have
competing effects. We initially looked at amines in green tea. Green tea contains
GABA (gamma-aminobutyric acid) with a dry weight content in leaves of approx.
50μg/g (Syu et al., 2008). GABA was a possible modulator of PrAO as discussed in
chapter 1, section 1.5 and 1.7. In plants, GABA plays a metabolic role and in
mammals acts as a potent neurotransmitter (Anju et al., 2014). This small molecule
has the potential to be either a substrate for PrAO which could potentially have been
the cause of the increase in rates or an inhibitor. However, GABA showed no effect
on PrAO activity when tested to a concentration exceeding the possible dry weight
content found in green tea (see Table 3.3).
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Other prominent bioactive compounds in Green tea are the green tea polyphenols.
Although they lacked an amine group there was a possibility that they might react with
PrAO

bound

copper.

Epicatechin

(EC),

epicatechin

gallate

(ECG)

and

epigallocatechin gallate (EGCG), (Fig 3.6) were all tested due to their reported health
benefits (see Section 1.8). When screened against PrAO, the three catechins mimicked
the findings originally found with green tea extracts (i.e. an increase in rates with
higher concentrations with inhibition being observed at lower concentrations,
especially with EGCG and ECG, suggesting further study was appropriate.

These findings were unusual since they were carried out using pure compounds and
therefore could not be due to competing components in green tea extracts. In an
attempt to further understand the observations, we used a UV spectrophotometric
assay (see section 2.5) to monitor PrAO inhibition. This assay directly monitored
benzaldehyde production at 254 nm. The results generated from monitoring
benzaldehyde using the spectrophotometric assay showed inhibition for EGCG (Fig.
3.9) and ECG (Fig. 3.10), but not for epicatechin (Fig. 3.8).

This finding suggested that epicatechin was somehow acting as an inhibitor in the
coupled Holt assay method but not when the catalysis was monitored using the direct
spectrophotometric assay monitoring benzaldehyde production. Furthermore, the
concentrations of EGCG and ECG required for observable inhibition were also greater
when monitoring rates using the direct spectrophotometric method indicating
systematic interference with the Holt colorimetric method.
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Further investigation of the Holt method of PrAO inhibition monitoring resulted in
clear interference by green tea catechins resulting in false inhibition of rates through
H2O2 sequestering. This affected all findings with catechins when monitoring PrAO
activity relying on H2O2 production, namely the Holt colorimetric method. This
observation was confirmed by adding a low concentration of H2O2 to the colorimetric
dye solution, whereupon formation of the pink quinoneimine dye was not observed
compared to a control equivalent.

Similar H2O2 scavenging was noted with the Holt assay method by Fernando and
Soya’s lab (Fernando and Soysa, 2015) when testing other phenolic compounds
extracted from plants as noted in chapter 1, section 1.8.

Once catechin H2O2

sequestering was confirmed all inhibition characterization was carried out using the
direct spectrophotometric assay. Epicatechin was shown to not inhibit PrAO when
assayed using the direct spectrophotometric method. The same observation was found
for EGCG and ECG (except requiring higher concentrations of both compounds);
these being an increase in rates at high concentrations of EGCG and ECG and at lower
concentrations an inhibition effect was noted. It was noted that control experiments
with both catechins and substrate without enzyme present was producing an apparent
rate using the Holt and direct spectrophotometric method but it was unclear what
metabolite was being formed. These confusing results required the need for a further
change in assay method to fully elucidate what was occurring.

4.3.2 HPLC Method Development
In order to fully elucidate what the anomalous inhibition/activation profile was due to
an HPLC method was developed to separate products and separately monitor
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benzaldehyde production. For this method to work effectively a suitable mobile phase,
separating column and flow rates were devised. A standard curve of pure
benzaldehyde was prepared (Fig. 3.4). Enzyme assay times were increased from an
average of 15min to 3hrs so as the production of benzaldehyde by the enzyme would
fall within the standard curve range for accurate activity monitoring of PrAO. A
control assay was performed to show that benzaldehyde production by PrAO was
linear over this time period (Fig. 3.5).

4.3.3 Deamination of Benzylamine by Catechins
It was found, with the aid of the HPLC method, that an increase in peak area for
benzaldehyde production at higher EGCG or ECG concentrations was observed (see
Fig. 3.11 and 3.12). At lower concentrations an inhibition effect was evident matching
the results obtained with the spectrophotometric assay at 254 nm (see Fig. 3.9 and
3.10).

When the HPLC assay was run in the absence of PrAO benzaldehyde formation was
still observed at high concentrations of EGCG and ECG. This non-enzymatic
formation of benzaldehyde clearly accounted for the observed activation seen at high
concentrations of EGCG and ECG (see Fig. 3.9 and 3.10). This type of non-enzymatic
reaction between benzylamine and catechins was a complicating factor in measuring
inhibition of PrAO by catechins.

A search of the literature revealed that Akagawa and co-workers (2005) had previously
described this type of non-enzymatic reaction between polyphenols and benzylamine
to produce benzaldehyde. They briefly mentioned the possibility that PrAO inhibition
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testing could be compromised by catechin deamination when benzylamine was a
substrate.

It was clear that the confusing activation/inhibition profile we had observed was due
to a mixture of factors: firstly, there was a reaction between some catechins and the
components of the colorimetric assay. More significantly there was a non-enzymatic
reaction between catechins and benzylamine producing benzaldehyde. This latter
reaction was more pronounced at high concentrations of catechins and was almost
absent at low concentrations. This clearly interfered with the assay methodology in a
manner that gave the impression of higher activity at high concentrations.

4.3.4 Subtraction of the non-enzymatic Deamination Reaction by Catechins
In this experiment, benzylamine and inhibitor (EGCG and ECG) were left to
deaminate in the absence of enzyme. A parallel experiment was run using identical
concentrations of benzylamine and catechin but including PrAO. Benzyaldehyde
formation in the non-enzymatic reaction was subtracted from that of the reaction in
the presence of enzyme (see Fig. 3.11 and 3.12). Once the background deamination
reaction was removed inhibition of PrAO was evident (see Fig. 3.11 and 3.12).

When comparing EGCG and ECGs ability to deaminate benzylamine, EGCG is
approximately 4 times more efficient than ECG yet has similar potency of inhibition
when the deamination reaction is subtracted. This would suggest that the deamination
reaction neither causes nor contributes to PrAO inhibition and provides further
evidence that EGCG and ECG are directly inhibiting PrAO.
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Finally, we found that another polyphenol, caffeic acid, produced a deamination
reaction with the substrate benzylamine. However, subtraction of the non-enzymatic
rate showed no inhibition of PrAO for this polyphenol (Fig. 3.15).
While inhibition is difficult to assess when competing reactions are being examined
our findings indicate that the possibility that catechins directly inhibit PrAO cannot be
ruled out.

4.3.5 PrAO Substrates that may deaminate
A range of PrAO substrates were tested to explore whether the same deamination
reaction would occur. Methylamine, spermine and spermidine, all known PrAO
substrates (see Section 1.5) were screened. Screening was unsuccessful due to these
compounds either absorbing strongly in the 254 nm region or the inability to detect
product being formed, leaving only H2O2 to monitor which would be affected by
reacting with catechin giving rise to assay interference.

4.3.6 Gallated Polyphenol Inhibition of PrAO
Since EGCG and ECG inhibited PrAO and epicatechin did not it was hypothesized
that the gallate moiety of the compound might be responsible for the inhibition
observed. In order to explore this in more detail other gallate like molecules were
screened such as; gallic acid, methyl gallate and a related, non-phenolic trigonelline.
None of these compounds were found to inhibit (see Table 3.3) indicating the whole
molecule to be necessary to have an inhibitory effect.

Gallated polyphenols have been shown to interact with and modulate a series of
enzymes most probably through hydrogen bonding to the many phenolic groups
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present allowing for interaction with varying hydrogen bond accepting and negatively
charged amino acid side chains. Other studies add weight to this hypothesis like that
of Sánchez-del-Campo and co-workers (2009) who examined how human
dihydrofolate reductase (DHFR) was inhibited by EGCG and ECG but interestingly
not by other non-gallated catechins. The binding of ECG and EGCG were proposed
to be due to the 7 or 8 phenolic groups present and their ability to act as hydrogen bond
donors (Sánchez-del-Campo et al., 2009).

A study by Hara and Honda (1990) showed that α-amylase was non-competitively
inhibited by gallated catechins and less so by the non-gallated type as indicated by
ID50 measurements: ECG 130µM, EGCG 260µM, other non-gallated catechins and
Gallic Acid were above 1000µM. Additional inhibiting molecules included theaflavin,
theaflavin mono-gallates and theaflavin di-gallate (Hara and Honda, 1990), Such
findings align with observations in this study: the two catechin gallates of EGCG and
ECG inhibit in the mid to low micro-molar range, while the non-gallate epicatechin
displays little or no effect.

4.4

Molecular docking of Selected Catechins with PrAO.

4.4.1 Residue Binding Interactions and Location of ECG, EGCG and
Epicatechin on PrAO
In this study, and for the first time, ECG, EGCG and epicatechin were all
computationally screened to explore potential binding sites and binding interactions
with PrAO. ECG had a top rank docking score of -5.76 (Gbind). The predicted
hydrogen bonding interactions occur with the gallate phenol group of ECG binding to
the primary amine of the PrAO residue Asn231 and between other ECG phenol groups
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and the PrAO primary amine of Asn469 as well as the hydroxyl group of the side chain
Thr466. Hydrophobic contacts were indicated with side chains Leu468 and Pro237.
Binding of ECG is shown to be externally at the base of the wide funnel near the active
site where it completely blocks the active site entrance indicating steric inhibition (Fig.
3.17).

EGCG with a predicted docking score of -6.91 (Gbind) had the most energetically
favorable binding of all three catechins tested. Hydrogen bonding is represented via
the phenol group of the gallate moiety of EGCG binding to the hydroxyl group of the
PrAO side chain residue Thr466 and also the EGCG ester group to the PrAO hydroxyl
group of side chain Tyr238. Hydrophobic contact was predicted with the side chain
Pro237. EGCG is externally bound at the base of the funnel and partially blocks the
active site entrance, indicating steric inhibition as evidenced with ECG (Fig. 3.19).
Epicatechin had a predicted docking score of -5.30 (Gbind) when bound to PrAO.
Ionic charged interactions were shown for both side chains Thr466 and Tyr238 via the
phenol groups of epicatechin. Hydrophobic contact is with Pro237. The binding of
epicatechin is shown externally at the base of the funnel but is seen not to block the
active site entrance (Fig. 3.21).

As can be seen from the findings, residue side chains involved in ionic type bindings
were Asn231, Asn469 Thr466 and Tyr238 while notable non-charged interactions
were predicted with Pro237 and Leu468. These findings indicate that compounds with
phenol group arrangements around their structure as with green tea catechins or, as
shown by Hara and Honda’s research, other phenolic compounds such as theaflavin,
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theaflavin mono-gallates and theaflavin di-gallate (Hara and Honda, 1990) may have
an improved inhibition of PrAO.

4.4.2 Comparison of Computational Docking Results and Experimental Results
The computational results for ECG, EGCG and Epicatechin correlate with the
experimental inhibition screening of PrAO with the catechins examined in this study.
Both EGCG and ECG inhibited PrAO in the low micromolar range while epicatechin
did not. In the modeled binding of ECG and EGCG the gallates were involved in
hydrogen bond interactions with PrAO with EGCG showing the ester group also being
involved.

A similar study by Glisan and colleagues (2014) examined tea polyphenols ability to
inhibit digestive enzymes such as pancreatic lipase. EGCG non-competitively
inhibited this enzyme in the micromolar range where computational modelling studies
predicted that EGCG interacted with residues around the active site and therefore,
hindered substrate access and binding (Glisan et al., 2014). Furthermore, the phenol
groups attached to the catechins are primarily responsible for ionic binding
interactions of catechins (Fig. 3.17 and 3.19). Although patterns of inhibition could
not be reliably carried out in the present study due to the deamination reaction between
catechins and the substrate benzylamine a competitive inhibition pattern is the most
likely based on the computational models presented here.

4.5

Octopamine Inhibition of PrAO

Octopamine (Fig. 3.24) showed an IC50 value of 3.26 mM ± 0.8 mM when assayed
using benzylamine as substrate. A double reciprocal plot inhibition pattern showed a
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mixed inhibition pattern (Fig. 3.27). Physiological concentrations of octopamine in
blood plasma of humans were found to be in the range of 0.0026 +/- 0.0014 μM
(Yonekura et al., 1988), indicating that this compound to have little physiological
effect. In the literature there is conflict as to whether octopamine is an inhibitor or
substrate. In one study octopamine is reported to act as an inhibitor and in others
(Castillo et al., 1998; Visentin et al., 2001) to act as a weak substrate. To test whether
octopamine was a substrate or an inhibitor it was added to an assay mixture at a
concentration of 50 mM. The reaction was monitored for 15 minutes using the Holt
colorimetric assay method at 498 nm for evidence of catalysis and production of H2O2.
No rate was observed, leading to the conclusion that octopamine is not a substrate for
bovine PrAO but an inhibitor.

To further investigate octopamine inhibition similar structures of 4-aminophenol and
4-acetoamidophenol were examined for inhibition of PrAO. 4-aminophenol is the first
hydrolytic product of the breakdown of the mild analgesic 4-acetoamidophenol (Fan
et al., 2011) and is different to octopamine in having one less carbon and hydroxyl
group. Conversely, 4-acetoamidophenol (paracetamol) differs from 4-aminophenol by
an addition of an acid group attached to the nitrogen forming an amide bond. Neither
of these two compounds showed any inhibition of PrAO suggesting that the distance
of the primary amine from the main phenol structure is key to enzyme modulation.

4.5.1 Inhibition of PrAO by Quercetin
Quercetin (Fig. 3.28) is a flavonoid that is ubiquitous in foods ranging from plants and
vegetables to teas and wines. It is an antioxidant that is thought to protect against
various diseases including cancer, diabetes, lung and heart disease (Boots et al., 2008).
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Flavonoids, in general, are known to have strong antioxidant properties mainly due to
their aromatic hydroxyls groups and can scavenge reactive oxygen and nitrogen
species (Li et al., 2007). Quercetin consists of two polyphenol rings linked by a
pyranose ring structure (Day and Williamson, 2001). In this study, quercetin gave an
IC50 of 52.20 μM ± 33.75 μM.

Previous studies (Lee et al., 2002) have shown moderate PrAO inhibition by quercetin
through a using zymogram staining. As part of the current study, Rutin, a glycoside of
quercetin was also tested at 1 mM and 0.5 mM concentration and showed no
significant inhibition.

4.5.2 Additional Phenolic Compounds Screened for PrAO Inhibition.
Other phenolic compounds examined were tetrabenzine and umbelliferone.
Tetrabenzine is a xenobiotic drug used to treat a variety of hyperkinetic movement
disorders by reversibly binding to the type 2 vesicular monoamine transporter
tetrabenzine as an antichorea therapy in Huntington disease. This drug showed no
effect on PrAO.

4.6

Amino Acids

Amino acids were of interest in this study due to being found in the diet and having
primary amino groups (chapter 1, section 1.5 and 1.7). This would suggest that these
compounds could be potential substrates or inhibitors of PrAO. In this study, eleven
amino acids were tested at concentrations of 1 mM and 100 μM. Only two of these
eleven amino acids gave significant inhibition at 1 mM concentrations, L-cysteine and
D-norvaline.
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4.6.1 L-lysine inhibition of PrAO and Testing of Similar Amino Acids
Previously L-lysine was reported as an uncompetitive inhibitor of bovine PrAO in the
presence of H2O2 with a Ki value of 103 ± 14 μM with benzylamine as the substrate
(Olivieri et al., 2010). Ornithine and Arginine showed no inhibition of PrAO (Fig.
3.54 and 3.56).

4.6.2 Cysteine inhibition of PrAO and Testing of Similar Amino Acids
Cysteine, a short chain amino acid with a thiol group showed a significant inhibitory
effect (P ≤ 0.01). Cysteine is a low abundance amino acid that is highly reactive,
polarizable and redox-active (Marino and Gladyshev, 2012) At a 1 mM concentration
L-cysteine gave an inhibition of approximately 50% (Fig. 3.52). Cysteine contains a
thiol group, which becomes reactive at neutral pH; the thiol group reacts with metals
such as copper (Kim et al., 2014) and may directly interact with PrAO’s copper atom
in the active site. Human blood plasma concentration of cysteine reported is 197.00
(+/- 56.00 μM; Pastore et al., 1998), and based on the results of this study suggests
that cysteine at the typical blood plasma concentration may have an effect on PrAO
activity. To test if the thiol groups were significant in the inhibition of PrAO, the
structurally similar amino acid, ethionine, was examined. This showed no inhibitory
effect, indicating that thiol groups alone were not important (Fig. 3.55).

Alanine, having a methyl group side chain shoed no inhibition. Longer chained amino
acids, namely Iso-leucine and norvaline, were examined as they have one more carbon
on the side chain compared to cysteine, with methyl groups attached. Iso-leucine being
the same as norvaline except for an additional methyl group branching off, showed no
inhibition, but norvaline displayed an approximate 12% inhibition (Fig. 3.53).
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Phenylalanine showed no effect on PrAO. Serine and Threonine showed no effect on
PrAO.

4.7

Modulation of PrAO by selected Vitamins

Vitamins which are naturally found in the diet and important for human health were
examined for PrAO inhibition.

4.7.1 Pyridoxine Inhibition of PrAO
Pyridoxine inhibited PrAO un-competitively with an IC50 result of 5.55 mM ± 2.81
mM. Physiological concentrations of Pyridoxine found in human blood plasma were
reported as 0.025 μM (Gori et al., 2006) which may not be sufficient to have any
significant physiological effect given the IC50 result found in this study. Interestingly,
studies carried out with rabbit lung and heart membrane bound PrAO found that
another form of the vitamin B complex pyridoxamine inhibited these forms of PrAO.

4.7.2 Inhibition of PrAO by Thiamine (Vitamin B1)
Thiamine (Vitamin B1) was an inhibitor of PrAO with an IC50 value of 5.046 mM
±1.15 mM. Physiological concentrations found in blood plasma can be as high as 0.12
μM (Hung et al., 2001). The fact that a competitive inhibition was observed indicated
that this molecule binds in the active site competing with substrate binding. Interaction
could be via the positive charge on the imidazole ring structure binding to the negative
charge of TPQ, while the amine group on the pyrimidine ring could possibly hydrogen
bond to nearby polar residues Asn469 or Tyr383.
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4.7.3 Other Vitamins Assayed
Vitamin B12 and riboflavin (B2) were tested. Vitamin B12 was of interest based on
the six primary amines attached to its structure, therefore qualifying to be a potential
modulator of PrAO. Another B vitamin of interest was riboflavin (B2), due to the
hydroxyl and amine groups present. However, both showed no significant inhibitory
effect on PrAO (see Table 3.3).

4.8

A Selection of Non-Dietary Compounds Chosen for the Testing of PrAO
Inhibition

4.8.1 Inhibition of PrAO by Benzylhydrazine
Benzylhydrazine IC50 results were 6.628 nM ±3.2nM (Fig. 3.67). Lineweaver Burk
plot results showed an un-competitive inhibition pattern. Studies with another species
of PrAO Arthrobacter globiformis, showed benzylhydrazine to be covalently bonded
in the active site. Findings showed a covalent bond forming a Schiff base to the C5
atom of the TPQ quinone ring whereby the reaction product is stabilized and prevented
from releasing an aldehyde in the first reduced steps of the ping-pong reaction
mechanism (Langley et al., 2008). Small molecule phenyl-hydrazine type structures
have generally been shown to bind either reversibly or irreversibly to the active site of
amine oxidases (see section 1.7). Phenelzine, a known PrAO and MAO-A inhibitor
(Wang et al., 2006) (see chapter 1 section 1.1), is structurally similar to
benzylhydrazine and was shown to be a reversible inhibitor in bovine PrAO from lung
tissue (Lizcano et al., 1996). Studies with similar hydrazine inhibitors have shown
effects arising from additions to the molecule. For example, it was noted that any
addition to the phenyl ring structure, such as a fluorine atom can effect selectivity
between MAOs and PrAO (Wang et al., 2006).
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4.8.2 Testing of Sulphanilamide for PrAO Inhibition
Sulphanilamides have been extensively used as a bactericidal compound (Venkatesh
et al., 2013). This molecule having a primary amine and sulphanomide group was of
particular interest in this study due to its similarity to known PrAO inhibitors.

4.8.3 Testing of Acrylamide for PrAO Inhibition
Acrylamide is a neurotoxic carcinogen that is gaining interest since it is produced by
the Maillard reaction from cooking carbohydrate rich foods at high heat (Basiri et al.,
2016) and is therefore naturally found in the diet. This molecule was chosen as it is a
small molecule with a primary amine attached and is readily found in the diet, but
upon testing had no effect (see Table 3.3).
4.9

Conclusion/Future work

Key results from this study highlight the key modulating roles that theobromine and
caffeine can have on PrAO. It would be of interest to examine a wider range of
methylxanthines with substituents at other positions for their effect on PrAO.
Moreover, there are a range of other bioactive compounds present in foods such as
rutin, curcumin, thymol, lupeol as well as a host of others that might be interesting to
test as PrAO inhibitors.

The extension of this work to studies on the human form of PrAO is another important
next step. If the inhibition is similar or even more pronounced it would be of
considerable impact. The results from this study indicate that consuming foods and
beverages containing theobromine like cocoa or caffeine may have health benefits
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associated with modulated PrAO. Moreover, the fact that theobromine can arise as a
metabolite of caffeine shows that inhibition may be prolonged by metabolites.

The effect of these compounds on other amine oxidases would also be of interest.
Thus, monoamine oxidase and plasma amine oxidase may also be inhibited by
methylxanthines, for example. This is of significance since these enzymes also play
critical roles in the body in the regulation of amines and especially neurotransmitter
metabolism.

The potential of green tea catechins to have an inhibitory role is suggested by the data
and requires future exploration. It may be that such inhibition is irreversible and it
might be possible to isolate an enzyme inhibitor complex. Mass Spectrometry of
native PrAO versus inhibited PrAO would be useful in this regard.

Finally, the compounds identified herein may act as potential lead compounds for the
discovery of novel PrAO inhibitors.
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